Accession	group	form	version	status	SampleID	aVisit	CSLRA_q1a	CSLRA_q1b1	CSLRA_q1b2	CSLRA_q1b3	CSLRA_q1b4	CSLRA_q1b5	CSLRA_q1b6	CSLRA_q1b7	CSLRA_q1c1	CSLRA_q1c2	CSLRA_q1c3	CSLRA_q1c4	CSLRA_q1c5	CSLRA_q1c6	CSLRA_q1c7	CSLRA_q1d1	CSLRA_q1d2	CSLRA_q1d3	CSLRA_q1d4	CSLRA_q1d5	CSLRA_q1d6	CSLRA_q1d7	CSLRA_q1e1	CSLRA_q1e2	CSLRA_q1e3	CSLRA_q1e4	CSLRA_q1e5	CSLRA_q1e6	CSLRA_q1e7	CSLRA_q1f1	CSLRA_q1f2	CSLRA_q1f3	CSLRA_q1f4	CSLRA_q1f5	CSLRA_q1f6	CSLRA_q1f7	CSLRA_q1g1	CSLRA_q1g2	CSLRA_q1g3	CSLRA_q1g4	CSLRA_q1g5	CSLRA_q1g6	CSLRA_q1g7	CSLRA_q2a	CSLRA_q2b1	CSLRA_q2b2	CSLRA_q2b3	CSLRA_q2b4	CSLRA_q2b5	CSLRA_q2b6	CSLRA_q2b7	CSLRA_q2c1	CSLRA_q2c2	CSLRA_q2c3	CSLRA_q2c4	CSLRA_q2c5	CSLRA_q2c6	CSLRA_q2c7	CSLRA_q2d1	CSLRA_q2d2	CSLRA_q2d3	CSLRA_q2d4	CSLRA_q2d5	CSLRA_q2d6	CSLRA_q2d7	CSLRA_q2e1	CSLRA_q2e2	CSLRA_q2e3	CSLRA_q2e4	CSLRA_q2e5	CSLRA_q2e6	CSLRA_q2e7	CSLRA_q2f1	CSLRA_q2f2	CSLRA_q2f3	CSLRA_q2f4	CSLRA_q2f5	CSLRA_q2f6	CSLRA_q2f7	CSLRA_q2g1	CSLRA_q2g2	CSLRA_q2g3	CSLRA_q2g4	CSLRA_q2g5	CSLRA_q2g6	CSLRA_q2g7	CSLRA_q3a	CSLRA_q3b1	CSLRA_q3b2	CSLRA_q3b3	CSLRA_q3b4	CSLRA_q3b5	CSLRA_q3b6	CSLRA_q3b7	CSLRA_q3c1	CSLRA_q3c2	CSLRA_q3c3	CSLRA_q3c4	CSLRA_q3c5	CSLRA_q3c6	CSLRA_q3c7	CSLRA_q3d1	CSLRA_q3d2	CSLRA_q3d3	CSLRA_q3d4	CSLRA_q3d5	CSLRA_q3d6	CSLRA_q3d7	CSLRA_q3e1	CSLRA_q3e2	CSLRA_q3e3	CSLRA_q3e4	CSLRA_q3e5	CSLRA_q3e6	CSLRA_q3e7	CSLRA_q3f1	CSLRA_q3f2	CSLRA_q3f3	CSLRA_q3f4	CSLRA_q3f5	CSLRA_q3f6	CSLRA_q3f7	CSLRA_q3g1	CSLRA_q3g2	CSLRA_q3g3	CSLRA_q3g4	CSLRA_q3g5	CSLRA_q3g6	CSLRA_q3g7	CSLRA_q4a	CSLRA_q4b1	CSLRA_q4b2	CSLRA_q4b3	CSLRA_q4b4	CSLRA_q4b5	CSLRA_q4b6	CSLRA_q4b7	CSLRA_q4c1	CSLRA_q4c2	CSLRA_q4c3	CSLRA_q4c4	CSLRA_q4c5	CSLRA_q4c6	CSLRA_q4c7	CSLRA_q4d1	CSLRA_q4d2	CSLRA_q4d3	CSLRA_q4d4	CSLRA_q4d5	CSLRA_q4d6	CSLRA_q4d7	CSLRA_q4e1	CSLRA_q4e2	CSLRA_q4e3	CSLRA_q4e4	CSLRA_q4e5	CSLRA_q4e6	CSLRA_q4e7	CSLRA_q4f1	CSLRA_q4f2	CSLRA_q4f3	CSLRA_q4f4	CSLRA_q4f5	CSLRA_q4f6	CSLRA_q4f7	CSLRA_q4g1	CSLRA_q4g2	CSLRA_q4g3	CSLRA_q4g4	CSLRA_q4g5	CSLRA_q4g6	CSLRA_q4g7	aProcDY
		CSLRA	1.0	expected	127029	b	209								36.8			77.2	122	936					1.47	1.34						1.61	1.61						3.38	4.1						7.78	2			.m																																											209					1.2			39.6			93.2	163	905					1.44	1.87						1.25	1.12						4.28	1.75						3.95	1.52			.m																																											
		CSLRA	1.0	expected	316214	b	240	2.25			1.53	1.53			7.93			150	107	505		4.29				1.43			3.59										10.4	2.12	3.33		3.32				1.16			.m																																											240	3.18			2.49	2.12			7.86			151	110	528		2.52				1.05			4.85				1.73	1.64		6.92			9.67	4	2.55		3.94				1.34			.m																																											
SUB230862	Atopic	CSLRA	1.0	expected	2671	b	63							56.46	40.51			278.95	355.88	3573.59	25.16								2.83				30.47	38.29	83.64				13.32	17.53	26.27	99.74					16.85	1.77	117.63	63					9.17	5.51	64.57	49.31			301.3	378.35	3577.26									16.71				22.72	12.86	89.1				10.44	16.29	22.12	64.57					10.09		164.47	63					9.06		46.85	39.56			260.24	416.55	2181.15													11.18	28.02	70.46				17.84	13.95	25.68		5.23				13.76	29.76	90	63						36.04	129.13	37.12		5.73	278.8	425.5	2301.27													10.75	16.02	133.98	8.34			16.4	15.97	23.31	36.55					11.72	2.56	123.42	173
SUB230863	Atopic	CSLRA	1.0	expected	1879	b	63					10.03	7.6	147.47	9.76			308.23	165.61	29900	26.5												10.53	74.21	106.65	7.31			14.3	386.02	1228.87					6.01	99.25	503.68		63						2.56	121.77	19.82			274.26	152.71	5001													10.09	51.49	104.94	4.15			12.29	385.16	1193.82					6.52	101.6	469.89		.m																																											.m																																											180
SUB230864	Atopic	CSLRA	1.0	expected	4015	b	63							487.7	80.71			312.12	682.03	9528													9.23	20.92	765.02		62.29	14.86	4.64	195.34	766.03			162.15	58.18	8.08	529.48	1014.68		63						8.27	514.25	81.91	6.78		272.55	686.3	5001													11.72	26.85	867.63		69.28	14.39	7.1	211.37	790.94			167.76	60.2	9.04	515.78	1085.27	5.57	63							468.04	76.06			283.43	641.4	13416														22.72	905.27		65.31	43.62	10.3	376.33	158.21						10.97	26.85	1055.19	63																										10.31	39.97	1022.6		75.44	46.99	12.09	373.64	121.78	11.51	14.22				8.46		1100.46	165
SUB230865	Atopic	CSLRA	1.0	expected	2369	b	63	7.31						179.56	48.86			349.06	509.85	2299												13.8	16.53	105.07	38.92					30.91	29.18					14.34	9.06	23.31		63						8.27	126.69	58.11			336.09	489.05	5001												13.8	19.56	122.76						28.93	24.5									.m																																											63																																							14.07	10.14	13.5		179
SUB230866	Atopic	CSLRA	1.0	expected	8383	b	64							2319.19	20.25			331.38	393.63	1582.23															3065.24		20.57	40.2	63.74	444.36	80.54	2.81					127.41	15.55	268.82	64							2153.17	14.1			311.24	370.05	1449.46															3221.93		17.77	32.15	58.92	431.05	58.8						121.82		249.27	64				23.19			2576.58	15.32			290.18	530.81	1620.54	18.1														5783.31			9.4	48.99	413.98		2.81				18.71	28.58		1328.98	64				22.04			2809.54	19.17			291.06	556.52	1627.33															6441.79			10.19	56.69	454.4	4.8					19.31	29.25	35.63	1377.32	149
SUB230867	Atopic	CSLRA	1.0	expected	7935	b	64							220.68				106.75	91.82	3704.96															653.4							1028.46							1023	64							263.6	9.98			127.64	101.34	3855.31															754.34							979.38							1077.63	64						8.49	421.36	7.57			83.46	122.93	4121.88	8.6														736.81							1002.54						2.88	1239.43	64						15.55	343.51	9.42			88.65	123.85	4182.42															751.64							888.3							1258.7	152
SUB230868	Atopic	CSLRA	1.0	expected	8495	b	64							69.82	23.5			735.41	447.69	3150													12.47							65.61							63.06	479.61		64						13.82	100.04	23.05			811.55	469.17	5001													12.87							64.04	8.49						62.31	491.74		64						0.86	92.46	24.79			611.85	543.86	2595																				50.99	24.06						19.98			64							49.89	22.9			620.79	592.58	5001																				50.65	13.82						20.01			147
SUB230869	Atopic	CSLRA	1.0	expected	2446	b	63	4.15						303.76	25.62			267.08	353.82	7452													10.37						29.53	9.23	13.5					12.26	8.82	43.85		63	8.34					4.07	254.06	40.63			290.62	379.03	5001									0.38				9.63		41.23				29.23	13.31	52.57					13.86	8.7	22.12		.m																																											.m																																											179
SUB230870	Atopic	CSLRA	1.0	expected	18594	b	67						8.63	369.15	21.15			204.6	257.47	2860.66									4.05						654.05						21.25	478.72						9.07	1209.15	67							310.38	18.41			175.91	233.14	2598.35														2.39	628.11						4.64	443.11						19.52	1211.08	67							299.28	18.86			136.25	218.36	2702.52	12.85													1.02	645							435.26						32.41	901.56	67						1.02	320.22	18.8			140.91	212.33	2713.41														15.18	748.52						10.82	469.67							842.5	113
SUB230871	Atopic	CSLRA	1.0	expected	10534	b	65							71	23.49			290.52	395.97	2860	17.53														20.69											7.4				65							40.95	21.97			337.49	413.38	5001														9.13	48.35											8.03	9.89		34.97	65							59.94	18.68			598.32	510.53	4399														0.36	62.69				15.12	14.41	26.77					7.15				65						4.58	65.45	17.94			533.84	522.92	5001															56.51				14.74	13.93	6.56									138
SUB230872	Atopic	CSLRA	1.0	expected	15875	b	66							163.92	47.08			153.78	264.46	4361	29.06													30.82	470.1						19.36	511.95					28.53	110.29	300.79	66						17.27	180.75	41.77			154.05	253.59	5001														10	351						20.92	366.58					24.74	62.15	263.36	66						24.56	201.21	31.65			140.38	258.42	4292	38.92													22.48	505.08						17.79	773.67							1168.77	66						4.81	190.98	32.62			133.05	235.03	5001	38.92													32.38	580.46						22.48	549.54						27.17	973.76	121
SUB230873	Atopic	CSLRA	1.0	expected	12001	b	65								7.71			57.84	104.91	4020	114																													65								5.84			50.75	90.46	5001																														65								6.03			47.21	105.33	3961																														65								9.78			56.39	122.08	5001	25.82																													129
SUB230874	Atopic	CSLRA	1.0	expected	20761	b	67							182.09	27.48			315.69	897.15	2038.82													8.04	2.39					13.09	35.44	6.42					9.6	13.37	13.44		67							175.6	30.1			300.49	921.82	1985.1													8.45	19.52					11.81	27.31						8.87	13.04	1.94		67							224.96	37.87			267.14	1345.61	1891.99																														67						8.18	211.62	32.4			229.87	1270.44	1750.38																														111
SUB230875	Atopic	CSLRA	1.0	expected	6367	b	88							15.86	7.59			156.71	56.93	3736.98																1.08				183.4	60.7						17.08			88							3.22	8.58			139.91	55.84	3413.36																				189.63	68.16						17.36			88							40.7	5.18			159.82	53.33	3865.27	8.69																			19.4	7.82						11.7			88							78.35	6.38			146.65	51.07	3639.13															7.63					18.04	0.86	13.85					10.25			195
SUB230876	Atopic	CSLRA	1.0	expected	21792	b	76							112.19	27.49			310.37	503.2	1124.12														0.93	18.93							34.41					54.97	40.63	27.37	76						2.55	137.73	32.4			321.4	474.19	1098.65														0.75								25.96					58.14	47.53	16.12	76						11.93	48.51	35.3			301.37	510.04	2917.88												25.13		26.19	733.22					40.47		21.74					19.21	6.3		76							88.1	42.86			371.87	524.25	2970.34												36.46		30.29	875.01					40.22	2.36	44.28					22.08	5.35		118
SUB230877	Atopic	CSLRA	1.0	expected	21341	b	75	8.98					9.08	90.96				26.06	26.28	13887															238.5					9.61	8.35	51.98						5.21	122.31	75							42.5				27.39	24.78	5001														7.37	174.42													6.17	142.77	76							113.61				35.28	58.2	18293															146.25							89.52						4.78	218.82	76						6.3	90.93	3.93			28.37	42.14	5001	16.12													9.78	221.67							110.77						1.1	304.52	112
SUB230878	Atopic	CSLRA	1.0	expected	26574	b	79								81.24			561.91	323.9	272.7														9.09																79								81.37			600.74	313.17	278.77														7.25																79								81.7			525.82	318.49	250.39																														79						7.25		101.8			623.83	364.74	260.83														8.53																106
SUB230879	Atopic	CSLRA	1.0	expected	8719	b	88								54.05			284.44	411.77	14022	27.57												8.53		11.81					19.62										88							41.62	38.62			217.8	312.25	5001															38.85					15.48										88								47.32			212.74	399.46	5057.4																				9.36		9.74								88							7.63	35.11			228.54	366.65	4761.56															37.92					8.84		25.65								149
SUB230880	Atopic	CSLRA	1.0	expected	33138	b	80						6.2	43.76	116.8			1277.26	836.61	1915.48														1.76					12.7	30.25	2.05					9.48	8.41			80						0.59	24.05	108.2			1362.61	818.05	1991.25																			11.85	29.19	4.41						8.09			80						2.49	16.4	152.14			1650.88	1075.9	278.75																			14.81	20.53	3.82					10.35		2.49		80							17.27	140.71			1601.68	1048.81	281.04																			15.05	20.47	2.93					9.53				93
SUB230881	Atopic	CSLRA	1.0	expected	34643	b	80						2.34	101.1	31.79			220	620.11	8469													7.76		7.15					9.93		69.35						6.2	163.69	80							103.12	30.93			224.9	607.94	5001														1.32	20.7					10.47	4.56	31.35						10.71	203.2	80						3.52	39.17	13.72			235.7	708.88	4800													10.78							38.42	1.76						83.95	1.76		80							6.14	14.96			222.39	734.46	3718.55													9.9	3.82						42.44	8.6						75.38	2.34		86
SUB230882	Atopic	CSLRA	1.0	expected	40550	b	98b								16.49			352.06	190.41	1903.77						15.23	11.22							9.45					11.97	10.25	32.31					8.31		20.06		.m																																											98b								20.25			326.33	194.5	2060.04																														.m																																											172
SUB230883	Atopic	CSLRA	1.0	expected	38002	b	98a								31.52			209.46	626.68	5749.1																				12.75										.m																																											98a								29.51			216.37	590.33	5125.5																														.m																																											179
SUB230884	Atopic	CSLRA	1.0	expected	42042	b	98b								236.93			161.8	1319.32	420.74														5.03																.m																																											98b	19.35			10.83	22.01	82.09		239.18			213.25	1315.87	460.5																												12.27		.m																																											170
SUB230885	Atopic	CSLRA	1.0	expected	41928	b	98b								21.34			50.4	394.87	738.31																				22.36	12.27									.m																																											98b								46.52			139.98	569.37	1706.92						41.84							24.39							96.66	36.07									.m																																											170
SUB230886	Atopic	CSLRA	1.0	expected	46106	b	99a	5.84					32.57		41.37			212.67	180.79	5005.6														56.91					56.61		80.41					8.06		33.67		.m																																											99a						15.17		52.37			198.09	192.66	5206.6		5.07					42.48							20.57					9.02	44.41	65.83					6.66	13.8	48.02		.m																																											161
SUB230887	Atopic	CSLRA	1.0	expected	41125	b	98b						1.85		10.56			151.67	100.8	2058.4					9.05	11.26	43.16							18.73																.m																																											98b											56.33	48.85	937.74																														.m																																											171
SUB230888	Atopic	CSLRA	1.0	expected	46530	b	99a								74.11			56.18	294.36	13094.3							34.77							51.34					12.56	30.36	78.16					7.82		74.79		.m																																											99a						26.01		85.27			56.66	279.57	13590							0.47							29.28							16.25							68.07		.m																																											159
SUB230889	Atopic	CSLRA	1.0	expected	47465	b	99a						41.38		48.89			142.44	246.78	6654						51.82	673.21						227.07	380.25					8.77	141.78	413.08						21.44	183.97		.m																																											99a								57.39			130.3	261.76	5161						52.34	384.93						160.17	416.61						73.61	586.52						21.25	197.77		.m																																											156
SUB230890	Atopic	CSLRA	1.0	expected	47601	b	99a						3.52		27.57			88.09	243.51	4938						24.7	43.59							13.02						266.49	60.25									.m																																											99a						13.02		41.85			87.51	219.58	3986						19.89	40.27							65.83						484.49	234.69									.m																																											156
SUB230891	Atopic	CSLRA	1.0	expected	25221	b	99b						22.74		47.08			138.24	87.45	3282							0.47							30.38							56.91						22.52	42.48		.m																																											99b								33.04			166.7	68.85	2057																				11.64	38.07						12.26	5.6		.m																																											155
SUB230892	Atopic	CSLRA	1.0	expected	32105	b	99a								32.88			223.38	335.46	4799.46							35.87							26.01						19.76	32.57							26.01		.m																																											99a								38.3			157.5	461.4	4975.5		8.77					61.36							26.01							18.4							75.91		.m																																											157
SUB230893	Atopic	CSLRA	1.0	expected	52475	b	100						14.81		39.41			414.37	516.93	1144.81						12.1							11.26							38.52							6.42	11.09		.m																																											100						13.38		45.29			588.2	451.1	1360.96						28.21	12.8						81.01	11.09						13.59							6.18			.m																																											145
SUB230894	Atopic	CSLRA	1.0	expected	44477	b	100						11.09		38.96			325.04	449.16	1317.65						10.67	12.8						13.35								25.59									.m																																											100						14.81		46.02			384.01	508.92	1418.7						10							5.43																	.m																																											137
SUB230895	Atopic	CSLRA	1.0	expected	46642	b	100						18.57		37.8			250.68	465.38	24934.6													15.09						22.94	32.13							65.71	258.73		.m																																											100								44.33			261.16	479.23	20738.7						6.66	23.24						6.1						13.12	182.5	160.26					8.53	9.1			.m																																											138
SUB230896	Atopic	CSLRA	1.0	expected	56673	b	100					4.27						54.71	46.18	1051.88													5.85							4.27	17.41									.m																																											100						17.7					69.92	41.28	1149.96							22.07							11.38							22.95						3.79			.m																																											135
SUB230897	Atopic	CSLRA	1.0	expected	27742	b	101								41.28			160.82	763.09	1785.08						8.33	7.95													86.65							11.9			.m																																											101								52.3			163.03	1046.85	2680.26						2.3	11.47							12.01					13.3	412.51	35.32						31.76	14.7		.m																																											127
SUB230898	Atopic	CSLRA	1.0	expected	39522	b	101								16.08			572.04	744.59	9405.3						71.6							47.23						14.52	910.34	466.32						106	13.09		.m																																											101								12.55			377.48	668.09	12421.3						104.17							99.42																	.m																																											130
SUB230899	Atopic	CSLRA	1.0	expected	29839	b	116								25.02			265.64	492.06	9208																														.m																																											116								19.14			244.24	406.36	10561																														.m																																											174
SUB230900	Atopic	CSLRA	1.0	expected	30404	b	116								12.84			53.63	269.74	116.58														9.35						69.19	13.55									.m																																											116								10.92			62.99	270.44	123.07						8.92														41.04							6.98			.m																																											171
SUB230901	Atopic	CSLRA	1.0	expected	58556	b	100								25.37			139.86	467.96	1161.36						6.01	14.53							13.95														21.78		.m																																											100						12.23		27.72			117.2	472.4	1130.49																				13.1	10.52									.m																																											129
SUB230902	Atopic	CSLRA	1.0	expected	54348	b	116								28.36			146.07	610.63	1600.12						28.74							23.43																	.m																																											116								22.95			117.38	533.12	1591.94													48.91																	.m																																											172
SUB230903	Atopic	CSLRA	1.0	expected	25669	b	116											62.88	256.82	509.06																				16.35										.m																																											116											57.52	198.18	524.86																				25.47										.m																																											168
SUB230904	Atopic	CSLRA	1.0	expected	30068	b	116								62.57			148.79	696.57	745.45																														.m																																											116								64.17			160.68	729.91	408.88																				11.75										.m																																											168
SUB230905	Atopic	CSLRA	1.0	expected	61377	b	116								25.39			215.14	671.69	460.41																				11.91										.m																																											116								31.21			269.96	819.17	767.19																			3.91	17.4										.m																																											166
SUB230906	Atopic	CSLRA	1.0	expected	31427	b	117								19.07			104.57	462.92	247.06						15.63													18.51	75.93						9.39	6.76			.m																																											117								20.73			115.22	501.61	296.77						5.71													24.91	41.68							15.98			.m																																											170
SUB230907	Atopic	CSLRA	1.0	expected	25445	b	117								319.62			114.68	1906.23	108.55																			12.56	21.56										.m																																											117								339.88			102.39	1884.65	83.79														1.38					7.73	19.54	0.42									.m																																											168
SUB230908	Atopic	CSLRA	1.0	expected	68480	b	116								23.62			109.02	329.53	335.07																			3.5	96.47										.m																																											116								12.64			92.81	203.72	866.68																				25.91							8.78			.m																																											162
SUB230909	Atopic	CSLRA	1.0	expected	49893	b	117						5.36		28.22			163.1	976.15	529.28																			11.99											.m																																											.m																																											.m																																											162
SUB230910	Atopic	CSLRA	1.0	expected	70801	b	116								168.81			396.75	1869.86	163.68						57.26													10.8	255.01	8.06					5.67	47.59			.m																																											116								162.08			475.53	1733.33	222.32																			10.69	207.92	8.22						39.89			.m																																											163
SUB230911	Atopic	CSLRA	1.0	expected	48638	b	116												38.73	259.73																														.m																																											116												44.03	201.35																														.m																																											181
SUB230912	Atopic	CSLRA	1.0	expected	54236	b	117								6.58			32.35	272.71	184.67																			8.61							12.03				.m																																											117											30.68	284.68	207.86							3.47												12.07							10.79				.m																																											159
SUB230913	Atopic	CSLRA	1.0	expected	45763	b	117								80.16			213.39	1229.99	117.31						46.06	114.17						69.29	61.44						23.59	51.64						28.37	37.63		.m																																											117								86.75			212.42	1286.78	126.47						20.71	47.97						59.96	30.69						22.92	53.39						24.45	20.61		.m																																											158
SUB230914	Atopic	CSLRA	1.0	expected	49333	b	117											28.97	303.71							17.58							10.34							26.3	8.02						7.56	7.24		.m																																											117								29.75			115.28	989.23	20.92						22.05							8.62							20.25	10.08						25.47	9.53		.m																																											157
SUB230915	Atopic	CSLRA	1.0	expected	65234	b	117											82.07	145.93	44.97																			9.64							7.47				.m																																											117											73.58	139.42	53.66																			13.62	4.63						9.21				.m																																											156
SUB230916	Atopic	CSLRA	1.0	expected	46868	b	99a	6.89							54.71			142.44	160.29	4672							29.28							23.83					7.34		2.49							15.17		.m																																											99a						43.59		53.87			145.57	177.02	4015							0.47						12.47								6.65									.m																																											158
SUB230917	Atopic	CSLRA	1.0	expected	25557	b	118								15.04			36.07	349.09	13854																			10.51	11.11						5.78				.m																																											118								16.36			29.73	349.35	10709																			9.42	10.27										.m																																											149
SUB230918	Atopic	CSLRA	1.0	expected	30631	b	118											149.4	439.35	2573.27																				14.85										.m																																											118								10.4			131.58	447.12	1976.48						41.34																								.m																																											146
SUB230919	Atopic	CSLRA	1.0	expected	53558	b	118								38.63			99.34	283.7	1985.59							6.37																							.m																																											118								36.38			126.05	282.53	3053.71																														.m																																											146
SUB230920	Atopic	CSLRA	1.0	expected	81478	b	118								21.91			155.05	469	595.99																				9.88										.m																																											118								18.94			124.84	443.02	671.67																														.m																																											144
SUB230921	Atopic	CSLRA	1.0	expected	84309	b	118								11.77			65.32	421	648.6						13.2														60.44										.m																																											118								12.86			69.33	440.47	2329.21																														.m																																											142
SUB230922	Atopic	CSLRA	1.0	expected	66693	b	117								197.16			170.58	1094.54	1267.72						9.91													14.96	262.11						7.94	51.02			.m																																											117						2.94		212.92			176.64	1164.95	428.29																			16.84	627.56	8.79						25.19			.m																																											174
SUB230923	Atopic	CSLRA	1.0	expected	93212	b	118											62.32	62.27	870.91																					4.42									.m																																											.m																																											.m																																											137
SUB230924	Atopic	CSLRA	1.0	expected	88936	b	118								38.05			378.35	734.18	140.04						23.35													20.08	191.11						9.84	18.34			.m																																											118								40.43			354.59	785.66	193.72																			23.04	211.38	12.01									.m																																											137
SUB230925	Atopic	CSLRA	1.0	expected	89486	b	124								96.61			277.1	1264.91	198.08														11.83					8.7											.m																																											124								83.27			205.3	1500.75	129.49																				4.54						8.14				.m																																											157
SUB230926	Atopic	CSLRA	1.0	expected	98337	b	124								33.76			159.03	542.16	8589																			8.87	12.4	3.78					10.13		1.37		.m																																											124								44.08			227.23	729.14	12747																			10.71	10.89						11.56	21.08			.m																																											150
SUB230927	Atopic	CSLRA	1.0	expected	95859	b	124								51.65			274.75	661.7	1267.46					109.29		24.34													194.18	110.76						75.16	15.24		.m																																											124								43.09			277	586.57	711.57					139.88		46.92													180.72	18.91						42.43	33.24		.m																																											142
SUB230928	Atopic	CSLRA	1.0	expected	94965	b	124											49.11	109.59	8632																				79.38								29.11		.m																																											124						5.44					48.85	101.1	5752														10.26						224.22	2.76							2.42		.m																																											139
SUB230929	Atopic	CSLRA	1.0	expected	90542	b	124						11.83					118.06	103.49	98.57														8.03														14.62		.m																																											124											96.82	128.84	78.47							4.78					6.62									4.78									.m																																											139
SUB230930	Atopic	CSLRA	1.0	expected	102028	b	126						11.11					86.03	145.1	21572														8.18						24.53										.m																																											126											64	133.1	21361																														.m																																											139
SUB230931	Atopic	CSLRA	1.0	expected	97781	b	126								309.65			1000.74	2653.73	1377.4						9.36							16.76						65.57	1411.11	54.97					9.55	31.95	3.65		.m																																											126								381.22			1160.28	2841.23	1442.14						23.15													23.01	687.64	39.82					8.15	22.53			.m																																											129
SUB230932	Atopic	CSLRA	1.0	expected	90168	b	147				3.37				6.98			207	200	6.57					5.54							5.68							13.9							13.9				.m																																											147				2.68				11.9			653	169	6.07					6.37							6.04							14.7							12.6				.m																																											254
SUB230933	Atopic	CSLRA	1.0	expected	89992	b	147				2.16				24.5			252	259	53.9					2.66							2.46							4.95							5.76				.m																																											147				1.85				23.5			298	256	52.5					1.49							2.83							6.45	2.98						4.74				.m																																											246
SUB230934	Atopic	CSLRA	1.0	expected	89706	b	147				1.58				14.9			62.7	322	42.2					1.99							1.76							3.5	64.4	1.56					2.13				.m																																											147				1.29				21.9			49.1	264	47.2					1.65							1.01							3.32	14.4						2.13	5.19			.m																																											245
SUB230935	Atopic	CSLRA	1.0	expected	90454	b	147				1.42				7.07			64.7	80.7	470					2.04														5.52	102						8.25	104	10.7		.m																																											147				2.09				10.5			63.5	103	773					1.05							48.2																		.m																																											247
SUB230936	Atopic	CSLRA	1.0	expected	89596	b	147				1.49				8.91			116	224	3430					1.05							1.38							5.03							3.68				.m																																											147				1.23				12.1			85.3	311	3440					2.68							1.63							5.3							5.41	1.81			.m																																											242
SUB230937	Atopic	CSLRA	1.0	expected	100431	b	147				2.93				21.7			680	422	350					2.61							2.02							4.98							4.79				.m																																											147				1.79				16.9			985	444	537					2.18	1.13						1.18							3.68							1.9				.m																																											240
SUB230938	Atopic	CSLRA	1.0	expected	105601	b	147				1.92				127			329	1020	9740					2.78	56.9						2.9	11.8						31.4	365	65					3.83	278	412		.m																																											.m																																											.m																																											235
SUB230939	Atopic	CSLRA	1.0	expected	90080	b	147				8.83				19.7			281	636	39.5					4.37							6.15							13.4	1.54						6.87				.m																																											147				7.84				25.6			213	664	23.3					5.06							5.35																		.m																																											233
SUB230940	Atopic	CSLRA	1.0	expected	90718	b	147				2.88				36.9			300	263	2720					3.15	10.3						2.93	9.52						3.4	196						3.35	22.9			.m																																											147				4.92																																							.m																																											233
SUB230941	Atopic	CSLRA	1.0	expected	116647	b	147								5.7			102	107	142						1.27													1.92	4.63						1.72				.m																																											147				1.69				5.17			128	86.3	222					1.85														3	4.72						2.93				.m																																											229
SUB230942	Atopic	CSLRA	1.0	expected	96446	b	147				2.54				19			59.2	452	3.37					1.36	3.39						1.99							5.62	19.7						3.91	9.12			.m																																											147				3.73				17.7			34.6	291	3.31					3.02							1.97							3.88	25.3						3.2	2.59			.m																																											229
SUB230943	Atopic	CSLRA	1.0	expected	117021	b	148				1.33				8.2			118	175	2850						6.33						1.62							7.31							8.28				.m																																											148								7.3			149	166	2480												1.22	8.24						5.62							10.9				.m																																											235
SUB230944	Atopic	CSLRA	1.0	expected	91048	b	148								1.54			762	46	5380						12.7							8.96						2.57							5.69				.m																																											148								2.6			923	44.4	3790					1.37	16.6							29.5						4.55	1.06							2.29			.m																																											234
SUB230945	Atopic	CSLRA	1.0	expected	107089	b	148								29.6			207	199	136						8.42						1.15	24.8						7.2	60						3.7	63.4	3.88		.m																																											148								34.9			194	225	161						15.4						1.02	18.5						6.67	8.96							30.9			.m																																											231
SUB230946	Atopic	CSLRA	1.0	expected	89046	b	159	1.36				2.03	22.1		38.7			128	326	314		1.71			1.72	348	50.9		1.46			1.23	175	29.4		1.16			7.93	150	30.2		1.48			5.73	7.72	23.6		.m																																											159	1.29				2.44	19.4		24.5			107	268	400		1.72			2.35	262	48.5		1.76				83.1	19.1		1.4			8.62	85.6	22.8		1.16			1.67	91.5	18.3		.m																																											287
SUB230947	Atopic	CSLRA	1.0	expected	108351	b	159	1.7			6.1	2.78	20.1		35.6			96.8	538	96.9		1.88			11.4	5.09	17.8		1.58			18.6	10.5	33.2		2.18			33.3	16.5	44.9		1.72			38.9	14.7	27.8		.m																																											159	2.41			5.28	4.03	19.8		33.3			131	581	88.5		1.74			22.1	15.6	27.3		1.84			13.6	3.38	33.2		1.82			42.7	59.9	28.5		1.68			33.3	4.41	26.1		.m																																											284
SUB230948	Atopic	CSLRA	1.0	expected	90256	b	159	1.27				1.41	22.8		73.6			169	365	522		1.5				2.73	48.9		1.99				2.17	16.3		1.7				17.5	200		1.48				5.02	59.7		.m																																											159	1.23				3.4	13.5																																					.m																																											281
SUB230949	Atopic	CSLRA	1.0	expected	116173	b	159	2				1.06	20.8		92.8			126	452	276		1.02			7.56	31.7	23.1		1.18			15.2	2.09	17.6		1.11			5.35	184	27.2		1.46			3.71	16.4	27.5		.m																																											159	1.46			1.35	1.68	20.1		87.3			134	463	998		1.42			8.33	19.6	24		1.84			11.5	2.46	18.3		2.01			5.59	50.9	28.8		1.38			6.5	3.13	16.8		.m																																											280
SUB230950	Atopic	CSLRA	1.0	expected	120158	b	159	1.05				3.78	24.8		35.7			214	252	445		1.54				22.5	31.5		1.42				31.7	23.5		1.21			3.43	7.98	29.5		2.05			1.76	9.36	31.9		.m																																											159	1.35				2.22	30.5		29.8			178	240	397		1.54				5.77	19.9		1				19.4	32.9		2.09			1.45	46.6	41.4		1.59			1.09	3.4	34.3		.m																																											277
SUB230951	Atopic	CSLRA	1.0	expected	90630	b	160											90.1	474	251						6.39																								.m																																											160											73.5	401	333																														.m																																											277
SUB230952	Atopic	CSLRA	1.0	expected	118232	b	160											147	278	686																										11.6				.m																																											160											101	237	429							3.86																							.m																																											275
SUB230953	Atopic	CSLRA	1.0	expected	120495	b	160								36.4			178	527	487														1.53																.m																																											160								27.1			156	752	395																														.m																																											275
SUB230954	Atopic	CSLRA	1.0	expected	127139	b	160											101	324	1670																				69.5										.m																																											160								4.25			108	358	1320																				83.6	18.4									.m																																											267
SUB230955	Atopic	CSLRA	1.0	expected	126808	b	160											157	240	786																														.m																																											160											183	266	719							1.9																					20.3		.m																																											265
SUB230956	Atopic	CSLRA	1.0	expected	125393	b	171								11.3			118	346	326						1.57							1.46						7.87	1.64							1.44			.m																																											171								8.13			88.7	319	200						5.93							15.6	7.89					6.25	9.04						3.49				.m																																											313
SUB230957	Atopic	CSLRA	1.0	expected	88760	b	164	2.41					15		6.32			64.6	220	1120						13.3	107		5.04			2.66	17.3	62.2		2.45			4.48	15.3	31.2					2.13	7.42	44.3		.m																																											164	1.36			1.58	2.42	20.5		7.89			80.8	236	1460					1.92	3.75	33.9		2.17			1.65	2.55	51		1.75			4.18	23.1	81.1		3.36			1.1	18.2	227		.m																																											276
SUB230958	Atopic	CSLRA	1.0	expected	126698	b	171								71.2			331	655	292												1.42							14.6							20.1				.m																																											171								65.7			350	788	162					6.54							2.5							11.1							9.96				.m																																											300
SUB230959	Atopic	CSLRA	1.0	expected	113876	b	171								68.7			126	398	484						2.91													6.73	1.28										.m																																											171								75.7			98.4	314	402																			6.63											.m																																											299
SUB230960	Atopic	CSLRA	1.0	expected	108681	b	164				1.96	1.49	30.7		25.5			66.6	289	901		2.54			2.75	29.1	33.3					3.3	6.17	20		3.4			17.7	8.61	34.4		3.2			4.54	6.39	24.3		.m																																											164	1.79			2.75	1.85	16.1		34.2			105	369	1220		2.21			5.04	13.3			2.66			2.48	3.13						7.54	16.2	33.3		3.61			4.42	9.31			.m																																											269
SUB230961	Atopic	CSLRA	1.0	expected	91268	b	164	4.87			1.13				35			208	424	1110		1.31			1.43	46.1	24.8		4.28			2.64	5.77	28					2.77	247	103		2.95			2.83	30.9			.m																																											164	1.79			2.17	3.16	31.2		40.2			187	399	917		2.45			2.86	25.8	40.2		1.88			2.88	5.21	44.8					4.02	298	104					1.58	28.8	31.2		.m																																											268
SUB230962	Atopic	CSLRA	1.0	expected	138627	b	171								15.4			79.3	308	98.4						5.36													2.19	4.86	5.97					1.61	1.62			.m																																											171								13.1			96.8	287	96.7						1.86																								.m																																											286
SUB230963	Atopic	CSLRA	1.0	expected	108571	b	164	4.07			3.61	2.52	17.2		28.9			191	629	546		1.21			3.7	11.5	19.4					5.07	3.51	22.7					8.48	31.7	40.2		1.79			5.11	2.76	17.2		.m																																											164	2.33			2.9	3.78			27.8			185	631	556		3.53			4.74	3.62						4.06	1.77	26.4		2.7			7.45	215	9.3					3.98	7.16	21.6		.m																																											257
SUB230964	Atopic	CSLRA	1.0	expected	112183	b	164	2.08			2.17	2.08			19			346	241	1220		2.74			9.96	2.08	49		2.87			6.15		13.9					11.1	2.52	15.6		2.17			9.92	2.55	20.5		.m																																											164	1.1			2.88	1.47			25.2			315	277	1050		4.19			5.07	1.92			3.82			5.94	1.77	11.6		3.94			15.4	2.03	23.2		3.4			8.32	1.64	1.79		.m																																											255
SUB230965	Atopic	CSLRA	1.0	expected	148292	b	171					1.08			22.5			136	1220	13800					3.2	191	2430																							.m																																											.m																																											.m																																											282
SUB230966	Atopic	CSLRA	1.0	expected	104437	b	164				1.51	3.29	30.2		34.6			160	511	2160		3.69			5.4	2.71	43.3		2.82			3.76	2.5			3.28			15	3.46	23.8		1.71			6.15	6.25	8.7		.m																																											164	3.4			1.96		52		23			138	580	2590					4.5	1.01	21.1		1.36			2.94	3.13	11.6					6.67	2.34	29.1									.m																																											252
SUB230967	Atopic	CSLRA	1.0	expected	107779	b	164	1.79			1.51	3.27	23.2		25.6			369	406	1490		3.44			1.94	2.71	15		2.78			2.84	7.02	35.5		4.28			8.61	3.4	63.7		3.78			4.18	16.4	28		.m																																											164	2.33			2.08	4.96	46.4		31			337	375	1130					1.33	2.34			2.62			2.03	1.8	15		3.53			6.52	4.11	31.2		2.58			3.28	3.62			.m																																											251
SUB230968	Atopic	CSLRA	1.0	expected	119658	b	186											23.5	23.6	11800													20.2																	.m																																											.m																																											.m																																											354
SUB230969	Atopic	CSLRA	1.0	expected	131830	b	186											27.7	73.5	5660					2.03		78.8												6.66	11.5						13.9	6.13			.m																																											186											25.1	44.3	5660												9.22							24.1	4.51										.m																																											348
SUB230970	Atopic	CSLRA	1.0	expected	108791	b	186								73.2			72.8	918	54.3					8.6																									.m																																											.m																																											.m																																											341
SUB230971	Atopic	CSLRA	1.0	expected	163555	b	186								129			907	281	553																			9.78											.m																																											186								66.8			398	431	216																														.m																																											340
SUB230972	Atopic	CSLRA	1.0	expected	162839	b	186								28			199	289	499					11.2							15.8							24.2		3.26					15.3				.m																																											186								44.1			289	405	790					10.6							12.1							44.2							58.7				.m																																											331
SUB230973	Atopic	CSLRA	1.0	expected	155067	b	186								65			114	492	464																				3.91										.m																																											186								154			341	427	503												4.66								38.7							4.86			.m																																											331
SUB230974	Atopic	CSLRA	1.0	expected	167548	b	186						15.1		4.92			14.1	125	2850							3.1							39.4						174	103							34.1		.m																																											186						10.5					9.95	107	2070							41							33.7																.m																																											330
SUB230975	Atopic	CSLRA	1.0	expected	112513	b	186								25.4			150	257	18100						12	39					4.66		38.7					51.3	55.6	94.3					7.12		47.8		.m																																											186						27.6		49.9			281	444	13900							15.7					8.12		4.16					55.3	33.7	42.6					9.49				.m																																											328
SUB230976	Atopic	CSLRA	1.0	expected	126918	b	186						18.2		79			74.6	343	93.8							11.9													24.6	7.26							20.1		.m																																											186								36.3			40.3	195	98.6														21.4						22.1	30.4					3.85		36		.m																																											327
SUB230977	Atopic	CSLRA	1.0	expected	167658	b	190								72.6			623	530	600					2.75	12.8	4.78					3.41	6.16						6.55	23.4						5.01		11.9		.m																																											190								64.6			650	490	2220					2.85	7.01						3.41		10.4					6.34	5.18	7.8					4.82		15.7		.m																																											351
SUB230978	Atopic	CSLRA	1.0	expected	168207	b	190						9.48		49.7			392	622	1240					1.42		21.5							7.18					6.75		57.3					1.48		15.3		.m																																											190						15.6		36.8			301	805	840					1.69		17.4							2.88					6.27		26.2					10.7		31.9		.m																																											348
SUB230979	Atopic	CSLRA	1.0	expected	109146	b	190				1.28				19.1			173	276	2160					2.39	7.99						2.08		20.6					11.9							4.2				.m																																											190				1.22		7.64		16.4			262	287	904					2.31	6.45	6.71					2.84							16		4.08					6.12				.m																																											347
SUB230980	Atopic	CSLRA	1.0	expected	162612	b	186				14.4		727		84.5			288	2860	33200					73.9	387	14100					36.1	266	6260					92.1	338	14400					60.9	153	4520		.m																																											186				18.6		670		69.2			270	327	3940																														.m																																											321
SUB230981	Atopic	CSLRA	1.0	expected	112403	b	190				1.09		5.11		122			1810	817	255					5.34		32.5					3.52		18.1					18.6	6.56	21.5					4.23		26		.m																																											190						12.7		112			1910	903	667					2.1		37.9					4.92		29.9					6.07		24.4					8.26		32.5		.m																																											334
SUB230982	Atopic	CSLRA	1.0	expected	124949	b	194								36.4			98.5	129	240						1.25							2.04														1.25			.m																																											194								32.9			106	147	344						1.18														1.02										.m																																											346
SUB230983	Atopic	CSLRA	1.0	expected	221669	b	194								7.8			73.1	253	1240						3.63							1.17							7.36	2.6						1.31			.m																																											194					1			10.9			79.2	315	5200						1.06							1.61						4.3	1.92							7.31	15.1		.m																																											346
SUB230984	Atopic	CSLRA	1.0	expected	168427	b	194					1.45			28.5			239	126	605						3.34							1.52								1.13						1.41	1.63		.m																																											194								22.3			246	107	316						1.62							1.09	1.32													1.68			.m																																											343
SUB230985	Atopic	CSLRA	1.0	expected	223544	b	194					1.19			22.4			150	258	206						4.74	3.17						2.5	1.45						1.94							1.08			.m																																											194					1.15			22.8			178	302	192						13.6							3.18							1.85	1.18						1.94	1.34		.m																																											341
SUB230986	Atopic	CSLRA	1.0	expected	168097	b	194					1.2	2.08		26.2			123	529	33.7						1.35							1.15							1.85							1.22	1.05		.m																																											194					1.03	1.22		26			156	561	30.3						1.83							1.07							1.5								1.76		.m																																											340
SUB230987	Atopic	CSLRA	1.0	expected	163067	b	194								17.6			65.5	298	70.7						5.56							1.9						8.03	1.92						9.55	1.6			.m																																											194								22.9			69.9	321	79.3						2.58							1.11						9.85	4.15							1.51			.m																																											332
SUB230988	Atopic	CSLRA	1.0	expected	126081	b	196								54.4			98.9	280	167						4.47							1.11						5.14	4.81							1			.m																																											196					2.37	10.2		58			107	539	175						1.14							1.27						5.84	26.7						2.01	1.05			.m																																											330
SUB230989	Atopic	CSLRA	1.0	expected	227180	b	196					1.04			12.7			34.2	310	13.7																				2						2.53	1.04			.m																																											196					1.02			12.3			36.3	270	13.1						1.4														1.17						1.99	16.5			.m																																											306
SUB230990	Atopic	CSLRA	1.0	expected	267205	b	196								45.9			153	560	10400						1.42							1.15						4.37	85.9	6.99						1.56			.m																																											196								39.1			126	422	9140						1.82																								.m																																											308
SUB230991	Atopic	CSLRA	1.0	expected	267425	b	196								40.3			100	213	100						1.2						3.16	1.21						16.8	2.52						1.63	1.02			.m																																											196								55.2			114	266	121						1.96							1.9						3.32	2.2						5.02				.m																																											304
SUB230992	Atopic	CSLRA	1.0	expected	135435	b	196								217			283	1360	91.5					8.49	75.2	791						9.79							117	3.4						5.07			.m																																											196								345			265	1380	173					8.84	38.4	1180						1.19							160	8.33						30.9	4		.m																																											300
SUB230993	Atopic	CSLRA	1.0	expected	113095	b	196								201			378	762	33.9					12.7	1.03						8.01							50.8	23.9	5.2					27.4	1.51	6.43		.m																																											196					1.21			171			245	563	34					9.97	1.29						4.89	1.02			1.06			42.7	21.9	7.02					28	1.63	4.53		.m																																											299
SUB230994	Atopic	CSLRA	1.0	expected	267315	b	207						1.72		14.4			83.8	147	1140							3.7							3.79							3.07							2.98		.m																																											207						2.37		11.9			87.6	134	1110						1	3.65							3.25							1.77							3.56		.m																																											356
SUB230995	Atopic	CSLRA	1.0	expected	273154	b	207						1.98		55.5			447	328	161					8.84		3.07					4.09		1.34					12.1		2.11					12.1				.m																																											207						4.56		62.1			343	377	144					4.95		3.25					4.48		1.77					15.1							13		3.79		.m																																											354
SUB230996	Atopic	CSLRA	1.0	expected	127851	b	207						3.52		68.4			376	314	301					1.77		3.07					2.08							17.5	84.2	4.33					2.45		1.85		.m																																											207						3.52		55			340	349	165						2.01	3.07							2.02					30.8	64	3.79					4.66		3.92		.m																																											353
SUB230997	Atopic	CSLRA	1.0	expected	230454	b	208								5.29			37.2	30.9	2860					1.24	1.53						1.02							2.49	66.8	1.17					1.52	4.69			.m																																											208				1				7.01			45.1	31.9	2740					1.19	7.69						1.06	1.58						1.53	129	7.87					1.54	8.33			.m																																											359
SUB230998	Atopic	CSLRA	1.0	expected	299564	b	208				1.48				97.9			166	1220	22					4.05	1.43	1.49					4.39		1.62					9.48	3.28						10.7	3.33			.m																																											208				1.3				87.6			141	858	41.2																														.m																																											358
SUB230999	Non-atopic	CSLRA	1.0	expected	268469	b	208					2.09	4.75		45.6			646	566	3980					1.49	1.61	8.23					5.07	1.61	3.59																.m																																											208																																9.05	16.4	6.74					4.7	7.57	13.5		.m																																											357
SUB231000	Atopic	CSLRA	1.0	expected	209170	b	208				1.01				37.9			157	459	410					1.46	1.73						1.17	1.9						1.91	2.62	1.43					2.15				.m																																											208								38.7			130	496	350					1.03	1.78						1.5	1.21						1.82	5.34						1.69		1.17		.m																																											354
SUB231001	Atopic	CSLRA	1.0	expected	162502	b	208				1.01		4.46		10.9			542	117	1590					2.12		2.21					2.12		1.33					20.7							4.82				.m																																											208				1.01		1.08		8.32			500	121	1930					1.56							1.95							20.4		2.15					7.31				.m																																											351
SUB231002	Atopic	CSLRA	1.0	expected	311627	b	208				1.83				345			717	689	31.2					1.47							1.4							1.87							3.21	2.03			.m																																											208				1.86		1.65		327			645	618	29.2					2.19	1.36						1.51														4.66	1.7			.m																																											347
SUB231003	Atopic	CSLRA	1.0	expected	265708	b	208				1.1		1.74		11.1			35.5	352	82.2					1.68							1.93		2.21					7.9	8.4	4.78					2.88		7.27		.m																																											208				1.29				12.7			41	510	99.7																														.m																																											345
SUB231004	Atopic	CSLRA	1.0	expected	276897	b	219								112			379	711	2800						3													19.2	9.31	3.15					6.48	1.41			.m																																											219								102			430	770	1870						1.65						1.24							24.6	17						8.26	3.54			.m																																											384
SUB231005	Atopic	CSLRA	1.0	expected	299454	b	219				2.48				8.79			35.8	43.6	65.8					4.16							1.35							5.59							4.08				.m																																											.m																																											.m																																											382
SUB231006	Atopic	CSLRA	1.0	expected	163445	b	219								46.9			178	395	1550						1.24							3.48						7.34	6.39	5.75					4.05	2.35	4.33		.m																																											219	1.76				1.5			48.8			193	395	2310						5.11			1.04				9.56						4.29	5.31	6.63					2.23	2.35	3.71		.m																																											379
SUB231007	Atopic	CSLRA	1.0	expected	276189	b	219	1.04			1.29		3.8		433			168	787	42.6					2.03	1.25	4.51					2.88		3.89					3.48	1.3	4.15					3.66		3.53		.m																																											219				1.49		6.1		409			147	1160	43.8					1.98	1.21	4.15					4.29		4.6					3.78	1.69	4.6									.m																																											380
SUB231008	Atopic	CSLRA	1.0	expected	254405	b	219				1.33	1.83	3.89		64.7			59.8	474	63.3					2.39	1.51	4.33					1.73	2.53	3.48					15	12.3	3.71					4.16	3.17	3.48		.m																																											219					1.89	3.57		79.8			63.2	511	198						2.17	1.88					1.33	1.39	3.26																.m																																											373
SUB231009	Atopic	CSLRA	1.0	expected	307314	b	219					1.81	4.69		40.1			191	350	257					1.95	2.55	4.24					2.36		3.98					6.09	1.56	5.17					4.77		5.39		.m																																											219					1.6	5.48		36.7			173	286	231					2	1.45	3.35					3.01	1.56	4.42					7.6	1.49	5.48					6.12		4.69		.m																																											370
SUB231010	Non-atopic	CSLRA	1.0	expected	314086	b	219	1.01			1.99		5.48		44.4			268	303	170					1.14		4.38		1.01					3.89					1.72	1.74	4.24					1.2		3.89		.m																																											219				2.25	1.29	5.3		35.2			214	294	185							4.46							4.15					1.74	2.77	4.95					1.69		4.64		.m																																											367
SUB231011	Atopic	CSLRA	1.0	expected	314196	b	219					1.46	5.48		50.7			251	198	6190							3.26							3.53					18.6	51.6	7.95					4.37	1.71	5.04		.m																																											219					1.29	1.79		45.3			227	193	6330						2.45	5.7							6.63					6.57	20.5	6.14		1.07			5.45	15	7.99		.m																																											365
SUB231012	Atopic	CSLRA	1.0	expected	230564	b	219	1.06					5.57		81.2			203	548	443						11.5	7.11						9.42	6.27					2.67	6.88	5.26					4.55	1.66	3.48		.m																																											219						3.71		78.8			182	474	406						7.05	7.2						3.52	4.24					3.04	4.22	4.42					3.49	1.73	6.36		.m																																											363
SUB231013	Atopic	CSLRA	1.0	expected	219514	b	219				2.36		2.81		15.1			86	98.3	46.6					6.54	1.54	3.98					5.89	1.92	4.33																.m																																											.m																																											.m																																											356
SUB231014	Atopic	CSLRA	1.0	expected	303012	b	224						2.72		11.6			59.6	115	43.4														2.39					2.66		4.33					2.21		10.2		.m																																											224						2.55		13.5			63.8	132	50.4							1.45							4.84					2.64		4.33					1.44		4.41		.m																																											371
SUB231015	Non-atopic	CSLRA	1.0	expected	284321	b	224						1.45		32.1			259	163	37.2					1.8							1.83		2.72					4.01		6.81		1.69			3.93	1.4			.m																																											224						3.06					15.3		397					1.58		5.27					3.7		1.54					4.13	1.96	2.72					8.46	2.04			.m																																											369
SUB231016	Atopic	CSLRA	1.0	expected	235114	b	232	1.59							8.16			88.8	157	4830		1.63			2.66		2.01		2.74			1.28		2.54																.m																																											.m																																											.m																																											386
SUB231017	Non-atopic	CSLRA	1.0	expected	270781	b	252				2.6	5.23	2.46		6.93				2.08						1.66	1.59																								.m																																											.m																																											.m																																											418
SUB231018	Atopic	CSLRA	1.0	expected	204542	b	224						4.07		112			394	297	2260					7.46		3.9					13	1.16						22.7	2.4	9.23		2.09			11.7	1.71	1.53		.m																																											224						4.75		109			499	255	1380					6.09		2.72					14.3	1.56	2.04					26.4		2.89		1.78			23.5	1.24			.m																																											359
SUB231019	Atopic	CSLRA	1.0	expected	214858	b	224				1.11		5.78		29.8			381	180	199					2.7		1.71					5.1		2.72					8.74		6.9					5.89		7.5		.m																																											224				1.13		3.56		26.7			402	206	229					2.3		3.82					2.97		2.13					5.31		3.82					3.27		5.95		.m																																											351
SUB231020	Atopic	CSLRA	1.0	expected	309549	b	227								85			181	995	2130																														.m																																											.m																																											.m																																											350
SUB231021	Atopic	CSLRA	1.0	expected	268248	b	227								13.7			145	80	7.13																			7.49	227	31.2									.m																																											227								17.4			133	72.7	9.04						1.18													21.5	325	117					1.66				.m																																											348
SUB231022	Non-atopic	CSLRA	1.0	expected	293802	b	227	1.83							5.83			54.6	57.3	10200																			5.32	2.67	9.25					2.69				.m																																											.m																																											.m																																											345
SUB231023	Non-atopic	CSLRA	1.0	expected	395843	b	227	1.95				1.47	2.47		20			117	250	334		1.48			1.06	1.1							1.46			1.86			2.63	25.3	3.23		1.13			11.1	771	81.5		.m																																											227	1.18				1.45	1.19		20.2			104	205	273		1.38			1.16	1.41	1.15						1.83	2.83		1.44			5.94	1.95			1.34			2.96	1.46			.m																																											313
SUB231024	Non-atopic	CSLRA	1.0	expected	363782	b	241	1.04				1.34			6.34			120	65	11.7						1.88							1.51							1.9							1.15			.m																																											241	1.05				1.74			6.76			122	77.5	12.3						1.01							1.36							1.1							1.04			.m																																											317
SUB231025	Atopic	CSLRA	1.0	expected	400568	b	241					1.17			34.3			603	569	7.59					4.49	1.26						5.34	2.01						13.9	3.63						6.04	1.26			.m																																											241					1.39			27.3			357	377	7.8					4.64	1.41						4.6	1.8						9.88	4.4						7.14	1.22			.m																																											307
SUB231026	Atopic	CSLRA	1.0	expected	420999	b	244								41.9			164	292	52.2					1.98							1.73							3.34							5.98	1.74			.m																																											244								34.6			124	256	67.9					1.54							1.31							2.99							3.2				.m																																											305
SUB231028	Atopic	CSLRA	1.0	expected	13594	b	76							36.53						8.23	10.52												5.07		25.96					231.46	5.92						18.98	5.54		76							37.23						18.5																				221.38	12.92						13.85	17.29		.m																																											.m																																											134
SUB231029	Atopic	CSLRA	1.0	expected	16662	b	78											7.22	139.9	1779.2																														78							11.73					59.59	1326.21																														78											14	197.04	1164.24																														78													78.42																														120
SUB231030	Atopic	CSLRA	1.0	expected	30975	b	89							165.75	7.79			188.58	302.78	866.26															115.32							233.67					22.69		75.55	89							171.41	8.92			208.75	306.08	955.03	14.5														97.66							261.45					25.59	5.51	65.19	89							220.97	6.17			165.99	302.7	740.86															158.59					19.85		204.13							292.78	89							220.44	6.17			190.89	303.16	829.61															165.24					18.9	8.57	207.8							159.61	147
SUB231031	Atopic	CSLRA	1.0	expected	27478	b	78												32.47	90.86																													8.1	78												22.22	76.13																						12.61							17.75	78											6.27	42.81	72.48														3.68															29.07	78											6.9	40.14	64.75																						19.42								117
SUB231032	Atopic	CSLRA	1.0	expected	31651	b	78							327.89	70.27			512.9	371.6	327.32															844.28							626.73							979.46	78							273.09	55.08			510.18	333.66	322.26														7.89	662.9							500.41							886.49	78							301.49	65.83			442	373.06	344.02															491.31							574.13						3.31	580.92	78							260.58	63.54			446.02	357.37	340.22															546.38							574.13							583.18	105
SUB231033	Atopic	CSLRA	1.0	expected	129113	b	98b								26.18			45.15	346.66	23.02																				8.99							30.43			.m																																											98b						8.01		31.13			51.22	360														12.19						13.54	20.39										.m																																											179
SUB231034	Atopic	CSLRA	1.0	expected	33487	b	98b								38.54			41.67	524.23	268.4														1.42						20.3										.m																																											.m																																											.m																																											180
SUB231035	Atopic	CSLRA	1.0	expected	46218	b	98b								9.24			41.47	143.07	148.54																														.m																																											98b								10.09			78.43	155.69	198.67																				9.59										.m																																											177
SUB231036	Atopic	CSLRA	1.0	expected	29362	b	98a								51.12			142.9	394.69	334.55																				10.03										.m																																											98a								55.41			139.92	466.08	321.63																														.m																																											191
SUB231037	Atopic	CSLRA	1.0	expected	44616	b	98b								18.64			175.06	338.18																															.m																																											98b								19.39			189.54	340.53																															.m																																											161
SUB231038	Atopic	CSLRA	1.0	expected	30863	b	98b								34.41			1428.66	320.54	482.75																											12.7			.m																																											98b								29.36			1055.56	321.78	1980.07																				12.34						9.13				.m																																											157
SUB231039	Atopic	CSLRA	1.0	expected	35581	b	101								11.08			375.87	130.46	302.72																														.m																																											101								12.36			372.14	125.51	423.89																														.m																																											159
SUB231040	Atopic	CSLRA	1.0	expected	34283	b	101						13.63		18.17			167.17	228.94	42.63																				20.91	13.09									.m																																											101						10.66		30.63			187.74	327.93	50.42																				18.8										.m																																											150
SUB231041	Atopic	CSLRA	1.0	expected	45535	b	101						10.93		58.53			439.54	623.02	661.18									9.49			8.37	3.27	9.85							16.84									.m																																											101								57.66			513.1	557.93	417.51																					6.58									.m																																											133
SUB231042	Atopic	CSLRA	1.0	expected	57560	b	101								18.37			111.65	231.75	92.54																				49.34							3.79			.m																																											101								20.63			159.98	217.89	147.74							12.28													28.1								13.09		.m																																											126
SUB231043	Atopic	CSLRA	1.0	expected	53782	b	101								37.35			369.22	796.04	2268.73																				40.94	22.16									.m																																											101						11.47		36.99			390.17	781.01	2546.89																				52.56	12.28									.m																																											123
SUB231044	Atopic	CSLRA	1.0	expected	50005	b	101								43.62			481.06	505.94	730.99																				30.08										.m																																											101						9.85		35.63			464.84	473.67	539.03																				19.02	7.13						11.68			.m																																											123
SUB231045	Atopic	CSLRA	1.0	expected	59987	b	101						6.58		10.59			20.66	72.09	639.94						6.07								8.22													0.29			.m																																											101								11.86			16.24	68.78	323.47														10.93																.m																																											124
SUB231046	Atopic	CSLRA	1.0	expected	57448	b	101								21.42			99.61	107.96	472.45						3.62														4.29										.m																																											101								16.92			93.64	82.79	178.88																				5.43	7.4									.m																																											124
SUB231047	Atopic	CSLRA	1.0	expected	60211	b	101								53.86			695.05	1032.98	289.61							7.67												7.49	3.45	24.28					4.69				.m																																											101								53.34			831.33	1029.36	352.58							9.85						5.43	10.66					6.88	5.57	15.5									.m																																											126
SUB231048	Atopic	CSLRA	1.0	expected	39980	b	101						12.55		47.63			270.15	607.78	526.31							8.22							16.3					8.15	43.63	6.58					9.95				.m																																											101						7.67		36.52			180.63	462.17	372.28													13.41						12.13	27.61	28.23					7.36		12.55		.m																																											115
SUB231049	Atopic	CSLRA	1.0	expected	39636	b	119								33.31			119.32	296.58	67.45							4.69												3.43							12.14				.m																																											119								21.54			69.27	222.33	46.3																					4.69									.m																																											170
SUB231050	Atopic	CSLRA	1.0	expected	54472	b	123											19.18	105.81	55.32														8.81																.m																																											123						31.77					29.69	123.34	64.18														5.89														2.23		.m																																											191
SUB231051	Atopic	CSLRA	1.0	expected	60099	b	119												84.15	98.84		8.44				64.45	86.72														10.82							8.09		.m																																											119												83.48	81.81																												9.16		.m																																											171
SUB231052	Atopic	CSLRA	1.0	expected	95613	b	123											11.66	23.55	185.06																														.m																																											123					6.98						9.21	16.77	183.4																														.m																																											149
SUB231053	Atopic	CSLRA	1.0	expected	97001	b	123								7.05			166.27	110.48	1066.94												6.61		4.09					7.65	16.35							14.04			.m																																											123											122.59	97.48	1026.63						5.99													6.56	37.57							33.82	5.3		.m																																											151
SUB231054	Atopic	CSLRA	1.0	expected	85414	b	123								14.29			238.86	351.61	175.57														0.93						8.36							6.32			.m																																											123								16.85			313.9	414.48	265.68							3.79							0.93						10.36										.m																																											160
SUB231055	Atopic	CSLRA	1.0	expected	87372	b	123								86.08			147.39	1526.75	118.71													6.1								2.23									.m																																											123						11.67		72.69			141.63	1369.19	106.29																					3.17									.m																																											159
SUB231056	Atopic	CSLRA	1.0	expected	85018	b	123								30.6			343.06	410.64	240.18													7.09						8.33	28.69							5.93			.m																																											123						3.79		35.8			361.69	365.71	146.93													5.88						7.9	30.16	19.44						8.31			.m																																											143
SUB231057	Atopic	CSLRA	1.0	expected	105491	b	126								8.96			19.61	156.39	62.88							10.14																							.m																																											126						0.99		10.49			20.14	173.92	33.95																														.m																																											134
SUB231058	Atopic	CSLRA	1.0	expected	84424	b	126						35.31					88.95	185.02	811.39														0.99													20.27	14		.m																																											126						66.82					123.53	265.07	1317.62																				13.07	3.65						38.83			.m																																											130
SUB231059	Atopic	CSLRA	1.0	expected	85788	b	126								15.76			52.12	682.55	10.63																			14.15	160.42	4.17							11.59		.m																																											126						6.19		29.3			137.5	987.92	39.37																														.m																																											116
SUB231060	Atopic	CSLRA	1.0	expected	86668	b	126											7.22	35.48	59.37							18.26																							.m																																											126											7.31	37.12	40.72							21.54																							.m																																											118
SUB231061	Atopic	CSLRA	1.0	expected	87086	b	126						8.67		8.11			32.44	413.91	586.96																														.m																																											126						2.08					18.05	351.25	457.15																					0.99									.m																																											120
SUB231062	Atopic	CSLRA	1.0	expected	84908	b	126						7.19					105.71	64.58	2789.75														15.9							3.65									.m																																											126											96.3	51.42	1660.05														18.73							4.17									.m																																											114
SUB231063	Atopic	CSLRA	1.0	expected	84534	b	126								11.55			303.13	272.15	1249.96																				38.94	3.13									.m																																											126								7.97			153.34	207.63	1028.87													12.42							152.82	54.97									.m																																											127
SUB231064	Atopic	CSLRA	1.0	expected	84622	b	123						3.17		8.19			61.16	285.84	231.5																				5.99	8.52									.m																																											123								11.94			76.46	315.17	78.45																					13.36							3.17		.m																																											140
SUB231065	Atopic	CSLRA	1.0	expected	86184	b	148				1.12		2.6		28.5			45.5	255	39.2					3.5		1.03							1.83					2.38	5.36	1.23					1.56				.m																																											148				2.93		1.92		23			44.1	225	40.6					3.4	1.83													1.27	5.25	2.6									.m																																											243
SUB231066	Atopic	CSLRA	1.0	expected	87724	b	148				1.38				5.88			33.7	666	43900												2.59	1.99						2.14		1.23					2.11				.m																																											148				1.84				4.82			39.1	534	34600							1.23					2.31		1.92					2.25							1.08				.m																																											243
SUB231067	Atopic	CSLRA	1.0	expected	94635	b	148								21.5			197	172	13.8					2.51								2.43	3.71					7.49	1.99						4.21	3.7	1.23		.m																																											148								23.6			274	146	14.3					3.63														4.28							4.07				.m																																											246
SUB231068	Atopic	CSLRA	1.0	expected	107891	b	148				4.77				23.7			705	149	14.9					13.5	5.67	1.41					26.7	3.34						7.65	24.8						18.3	6.18	2.26		.m																																											148				4.7	1.99			23			548	172	13.4					16.8	10.7						8.15	8.24						20.3	25.6	3.88					19.2	53.1	4.4		.m																																											235
SUB231069	Atopic	CSLRA	1.0	expected	116505	b	163				1.57		4.58		8.89			23.2	67	4					2.7		9.09					2.32	1.69	1.73					6.98	12.8	26.3					4.59	4.62	2.05		.m																																											163						8.59		6.81			16.8	61.7	9.58					2.06	2.01						1.28		11.9					4.93	7.33	7.17					3.4	2.98			.m																																											294
SUB231070	Atopic	CSLRA	1.0	expected	113324	b	163						18.6		17.5			62.9	283	117					3.85	3.73	9.58					2.4	2.58	1.07					5.71	9.57	5.62					3.27	2.78	4.19		.m																																											163					2.47	19.2		22.6			66.3	305	88.1					1.91		13.9					1.57		7.64					4.03	5.36			1.03			2.5	2.61	8.11		.m																																											294
SUB231071	Atopic	CSLRA	1.0	expected	108903	b	160						25.4						187	63.6							22.3							35.5							36.5							30.4		.m																																											160						30.2						78.4	52.5							52							13.5							32.4							30.2		.m																																											276
SUB231072	Atopic	CSLRA	1.0	expected	120840	b	163				1.25				15			57.3	481	42.8		1.11			1.81	3.51	10.1					1.36	2.19	5.83		1.34			11	72.9	5.41					7.69	44.5	5.41		.m																																											163	1.81					9.58		20.2			96.1	1050	35.2						2.58	10.1					1.32		15.3					26.9	111	25.3					3.33	20.9	3.07		.m																																											286
SUB231073	Atopic	CSLRA	1.0	expected	121405	b	148						1.75		2.34			472	35.8	926					26.4	8.38	9.85					1.7							23.5	6.82	7.29					2.59		2.09		.m																																											148					1.99	5.53		4.94			662	34.4	816					19.1	4.83	1.23					1.2							43.2	21.6	4.31					2.62	1.47			.m																																											223
SUB231074	Atopic	CSLRA	1.0	expected	114100	b	163						12.7		11.5			45.8	63.7	166					1.48	15.8	16.2		1.03				15	2.38					3.63	120	90.4		1.78			1.6	31.5	51.1		.m																																											163				1.67		6.27		13.6			55.1	82.4	291					1.1	12.7	5.2					1.66	8.7	28.1		1.84			2.96	9.95	60.3					1.91	119	226		.m																																											281
SUB231075	Atopic	CSLRA	1.0	expected	87548	b	163				1.22	2.23	12.7		3.4			155	110	3.8					1.07	5.74	4.19					1.58	3.1	14.1					1.54	2.72	3.8					2.57	4.67	11.1		.m																																											163	1.03			2.06		4.99		3.43			137	92.9	13.9					1.91	4.5						2.16		8.59					3.15	1.81	17.4					1.49		5.83		.m																																											273
SUB231076	Atopic	CSLRA	1.0	expected	88252	b	171					1.27	19.5		4.02			19.5	294	197						4.58	21.3						1.09	32.2						13	28.1						3	18.1		.m																																											171					1.7	22.2		3.87			18.7	271	206		1.13				3.69	20.3						3.09	18.2		1.07				17	20.3		1				4.4	11.7		.m																																											289
SUB231077	Atopic	CSLRA	1.0	expected	95413	b	179						4.82					1.45		8.36							7.64							14.7							24.6							20.1		.m																																											179						11.4					3.19		9.55							15.4							15.1					1.14		30.6							16.8		.m																																											343
SUB231078	Atopic	CSLRA	1.0	expected	110633	b	179				7.23		2.68		6.33			80.3	34	63.3					7.82		30.2					63.3		33.8					27.5		26.4					42		62.1		.m																																											179				6.3		5.33					36.2	24.9	46.7					4.06		9.1					6.42		30.8					39.5		31.9					16.8		37.8		.m																																											336
SUB231079	Atopic	CSLRA	1.0	expected	95189	b	179						14.9		8.34			53.6	98.9	327					1.74	4.75	7.49						2.8	5.85					7.23		1.3					3.05	6.85	7.35		.m																																											179						12.7		9.92			45.5	111	371						18.9	16.4					1.74	8.81	18.4					9.12		11.3					3.56	4.75	15.9		.m																																											334
SUB231080	Atopic	CSLRA	1.0	expected	87988	b	171						18.9					4.46	7.53	38.2		1				1.64	17.9		1				1.59	19						2.03	13.3						1.41	34		.m																																											171	1.07				2.37	30.2		1.98			39.1	39	54.7		1.05				2.78	36.5					9.12	1.93	25.4		1.03					32						2.08	31.2		.m																																											282
SUB231081	Atopic	CSLRA	1.0	expected	95301	b	179						17.2					6.06	14.2	11.1							12.1							6.38					12.7		25					2.76		9.25		.m																																											179						5.07					4.08	6.08								19.7							10.5					6.58		26.2					5		17.7		.m																																											330
SUB231082	Atopic	CSLRA	1.0	expected	100210	b	179						28.8		12.2			16.1	365	221							31.3							16.8							10.2						12.6	15.9		.m																																											179						10.8		13.7			12.2	444	286							37.4							6.66						9.34	8.65							6.93		.m																																											334
SUB231083	Atopic	CSLRA	1.0	expected	95749	b	179						13.5		40			83.4	240	151							4.32							7.21					3.03		32.7					1.55		10.3		.m																																											179						10.5		24.1			64.4	212	161							19.7							20.1					3.31	3.86	23.5					3.93		30.8		.m																																											331
SUB231084	Atopic	CSLRA	1.0	expected	103197	b	184	1.56			2.34		35.6		9.13			153	378	322		1.8			1.95	2.33	41.4		1.35			1.68	1.12	45.6		1.52			3.55	4.36	43.1		1.17			2.7	2.63	76.9		.m																																											184	1.17			1.95	1.06	45.6		8.95			168	353	1290					1.87	1.17	48.6		1.76			1.56		28.9		1.93			15.6	15.3	55.3		1.6			1.9	1.48	38.9		.m																																											340
SUB231085	Atopic	CSLRA	1.0	expected	163303	b	184	1.21			2.76		54		11.9			63.4	122	2410		1.43			2.6	16.8	50.2		1.51			1.85	7.1	57.4		1.97			3.52	16.3	52.3		1.38			2.78	2.64	37.7		.m																																											184	1.6			3.02	1.44	44.8		12.5			61.9	118	2840					2.45	3.46	27.3		2.29			1.26	5.66	46.5		1.17			6.1		42.7		1.09			2.09		41.4		.m																																											337
SUB231086	Atopic	CSLRA	1.0	expected	95077	b	185								22.6			199	204	31.1							24.2							2.29					2.63		21.9							6.23		.m																																											185								16.3			146	139	35.6							6.23							23					2.54		21.3							8.77		.m																																											326
SUB231087	Atopic	CSLRA	1.0	expected	156152	b	185						40.2		9.7			102	201	69.7							10							29.9					12		56.2					1.95				.m																																											185				1.63		11.2		9.73			113	231	55.7														24.2					5.42		14.8							37.9		.m																																											324
SUB231088	Atopic	CSLRA	1.0	expected	99020	b	185						6.23						4.54																													8.77		.m																																											185													4.86							7.52							8.77							16							12.4		.m																																											330
SUB231089	Atopic	CSLRA	1.0	expected	136627	b	185						3.31					25.2	51.2	173					3.04		23					4.44																20.7		.m																																											185											35.3	66	279							23					1.74									6.23					1.69				.m																																											324
SUB231090	Atopic	CSLRA	1.0	expected	92670	b	179						10.5		13.8			14.4	37.9	22.7							13.2					1.66		7.49					2.21		4.82							8.65		.m																																											179						8.07		18.9			13.9	39.5	24.6							23.5					1.33		12.4					1.96		16.4							10.2		.m																																											328
SUB231091	Atopic	CSLRA	1.0	expected	103869	b	184	2.23			3.52	1.07	57					2.97	2.03	34.3																			2.6	2.05	66.3		1.57			3.02	2.21	47.3		.m																																											184	1.49			3.55	3.32	34.7		1.09			4.84	1.9	69.7																1.39			2.54		63.3		1.23			1.87		37.2		.m																																											334
SUB231092	Atopic	CSLRA	1.0	expected	108003	b	190						18.4		103			95.9	916	498							20.9							17.1						47.1	6.56						53.4	29.9		.m																																											190						16		132			100	906	507							37.6							20.6					1.15	3.49	20.9							19.6		.m																																											360
SUB231093	Atopic	CSLRA	1.0	expected	103533	b	185						2.29		28.9			176	148	79.2					1.74														6.57											.m																																											185								25.5			159	178	68.6																			2.28		3.31									.m																																											335
SUB231094	Atopic	CSLRA	1.0	expected	100770	b	190						19.5		63.8			198	249	408					1.11		25.3							18.7					5.77	64	27.8					2.56	11.1	5.76		.m																																											190								31.2			471	77.2	720							19.3							4.43					3.17	49.5	14.2					2.54	7.79	21.8		.m																																											349
SUB231095	Atopic	CSLRA	1.0	expected	115816	b	194					1.8	5.16		43.3			98	466	21.3						1.79	5.92						1.69	4.74						2.04	5.94						1.79	5.3		.m																																											194					1.41	4.7		38.4			77.1	327	16.9						3.02	6.13						1.47	5.94						1.39	5.28		1.46			1.51	1.83	6.2		.m																																											346
SUB231096	Atopic	CSLRA	1.0	expected	136515	b	195								48.4			81.3	188	775																				14.4							1.69			.m																																											195					1.13			46.4			89.5	235	1280						1.04														3.72							1.36			.m																																											342
SUB231097	Atopic	CSLRA	1.0	expected	131234	b	194				2.79	1.86	6.44		71.4			141	433	131						9.78	7.56						1.72	4.88						10.3	7.51						1.33	4.6		.m																																											194					1.64	5.33		74.2			117	136	151						2.18	4.72						1.77	3.57						8.22	5.7						1.31	4.7		.m																																											337
SUB231098	Atopic	CSLRA	1.0	expected	167436	b	190				1.79				30.5			66.1	93	92.8					1.48							1							6.23							1.92		4.08		.m																																											190				1.51				26.3			28.2	60	54.9					1.3							1.09		9.32					3.02							2.04		8.56		.m																																											334
SUB231099	Atopic	CSLRA	1.0	expected	147054	b	190								8.86			27.9	92.6	59.8														19.8					3.44	7.59	8.87					1.1				.m																																											190								15.1			33.1	86.4	88.3														19.3					3.93		9.78							2.05		.m																																											335
SUB231100	Atopic	CSLRA	1.0	expected	139088	b	190						38.9		29.4			192	596	1400							28.9												1.03	68.4	42.5						25.2	88.1		.m																																											190						5.11		26.7			224	558	1200							38.9							12.8					1.25	39.4	68.5							35.7		.m																																											339
SUB231101	Atopic	CSLRA	1.0	expected	131470	b	190											9.36							1.27							2.14							2.37		2.37					1.81		2.88		.m																																											190											13.3		2.88																			2.39							1.64				.m																																											342
SUB231102	Atopic	CSLRA	1.0	expected	120728	b	194					1.92	5.78		118			131	1220	23200						2.01	7.07						2.75	3.87						2.59	6.8						2.23	7.31		.m																																											194					1.72	6.59		113			86.2	1110	26200						2.15	8.05						1.84	7.41					3.87	2.82	7.34						2.71	6.93		.m																																											332
SUB231103	Atopic	CSLRA	1.0	expected	121517	b	194					1.19	5.8		125			700	465	604						1.12	5.09							4.43		1.03			2.17	2.31	1.89						1.78	6.35		.m																																											194					1.56	6.49		98.5			556	380	568						1.23	4.79						1.52	6.88		1.38					7.73						1.94	5.12		.m																																											328
SUB231104	Atopic	CSLRA	1.0	expected	130544	b	194					1.06	6.64		64.8			130	97.2	1110						1.9	5.66		1.17				1.72						12.3	2.74	5.49					7.7	2.1	6.88		.m																																											194					1.7	6.88		40.3			87.2	67.8	1750						1.84	6.97						1.57	3.96					8.29	1.53	6.37					5.81	2.31	4.01		.m																																											330
SUB231105	Atopic	CSLRA	1.0	expected	120607	b	194					1.38	6.23		30			206	321	61.2							3.28						2.4	5.05					7.92	2.57	6.73					2.65	1.5	4.72		.m																																											194					1.13	7.07		28.2			178	318	48.1		1.55				1.22	1.89						1.31	4.43					3.23	2.43	5.59					1.73	1.83	3.85		.m																																											330
SUB231106	Atopic	CSLRA	1.0	expected	113988	b	194					1.04	1.65					175	311	40.6						1.57	4.26							5.14						37.6	6.47						6.91	6.9		.m																																											194					1.24	2.16					174	299	57.5							3.53							4.23					3.09	125	5.97						5.34	5.87		.m																																											343
SUB231107	Atopic	CSLRA	1.0	expected	222670	b	196					1.39	8.08		33.4			114	159	1400						11.4	12.5						2.57	7.87					11.8	135	10.2					4.12	115	6.22		.m																																											196					1.7	6.18		35.4			122	174	2050						6.61	10.1						1.63	8.71					12.4	12.8	6.46					2.43	113	10.4		.m																																											320
SUB231108	Atopic	CSLRA	1.0	expected	239157	b	196				4.08	1.4	4.21		15.1			722	90.3	259					5.2	1.49	3.02					5.92	1.57	4.92					20.6	1.57	1.65					19.1	2.75	5.2		.m																																											196				4.23	1.53	5.2		11.7			705	96.8	123					7.04	1.43	4.64					7.03	1.62	3.97					22.7	1.52	5.02					13.5	1.53	4.04		.m																																											322
SUB231109	Atopic	CSLRA	1.0	expected	204318	b	206					1			29			61.7	81	6.43						3.67							2.05							6.57							5.49			.m																																											206					1.29			26			36.5	112	7.19						3.55							1.54							22.3							2.17			.m																																											367
SUB231110	Atopic	CSLRA	1.0	expected	169738	b	206					1.24			147			160	1050	25.5						1.33							1.62						5.72	15.4							6.61			.m																																											206					1.12			160			173	1210	53.4						3.8							1.57						3.19	26.3							10.3			.m																																											373
SUB231111	Atopic	CSLRA	1.0	expected	121638	b	194					1.43	6.32		1.93			83.9	16.9	9.44						1.8	9.59						1.98	11.3					3.62	1.52	6.4						1.42	14.1		.m																																											194					1.54	6.01					73.1	13.9	10.4						1.55	8.81						3.02	9.84						1.83	6.78							20.1		.m																																											323
SUB231112	Atopic	CSLRA	1.0	expected	164749	b	196					1.36	8.22		18.5			76.3	115	761						2.01	11.7						2.13	11.5					3.99	1.55	6.67					2.82	1.83	13.1		.m																																											196					1.47	7.59		16			72.9	110	597						1.81	10.3						2.93	9.21					2.33	1.2	8.04					2.45	5.5	13.5		.m																																											320
SUB231113	Atopic	CSLRA	1.0	expected	208946	b	208				1.31		5.77		2.81			22.6	47	10.1					1.02	2.13	4.23					1.33	3.01	2.92					1.12	3.67	3.07						4.96	5.21		.m																																											208				1.31	1.91	5.15		7.59			62.2	83.1	12.8						2.42	3.01						2.36	5.52					1.19	5.59	4.01					1.05	15.1	2.46		.m																																											394
SUB231114	Atopic	CSLRA	1.0	expected	247037	b	206				1	1.35			468			460	933	41.7					1.25	2.42							1.72						14.4	144	4.17					1.81	3.35			.m																																											206				1.19	1.5			421			521	980	11.8					1.01	2.13							2.22						33.1	80						1.91	5.08			.m																																											364
SUB231115	Atopic	CSLRA	1.0	expected	130432	b	206					1.75			10.5			222	104	37.6						2.53							2.02							1.71							3.87			.m																																											206					1.64			13			112	139	140						1.92							1.56							1.77						1.08	21.6			.m																																											353
SUB231116	Atopic	CSLRA	1.0	expected	254515	b	209				1.43	1.17			4.44			118	60.8	25.1					1.45	1.48						1.38	1.34						2.73	1.82						3.6	1.29			.m																																											209				1.05	1.18			4.88			129	77.1	24.6					1.35	1.31						1.47	1.2						3.05	1.02						4.1	1.06			.m																																											364
SUB231117	Atopic	CSLRA	1.0	expected	154732	b	206								18.1			109	184	129						2.31							2.49						2.29	5.98						2.35	2.31			.m																																											206					1.24			26.3			113	207	1.24					1.39	5.43							1.68						3.04	4.73						2.36	1.77			.m																																											363
SUB231118	Atopic	CSLRA	1.0	expected	238474	b	206					1.24			6.86			48.7	35.9							2.08							1.76						57.1	11.7							3.75			.m																																											206					1.87			8.57			33.9	37.4						62	4.28						41.5	2.18						70	7.96	4.89						1.86			.m																																											354
SUB231119	Atopic	CSLRA	1.0	expected	300269	b	209					1.38			27.2			511	269	657					1.41	1.66						1.7	2.01						13.6	17.9						6.2	49.6			.m																																											209					1			27.8			756	255	632					1.89	2.15						1.66	1.88						22.4	34						8.92	34.2	7.38		.m																																											361
SUB231120	Atopic	CSLRA	1.0	expected	268579	b	218				3.44				19.7			91.1	74.9	21					4.92							2.44							6.58							7.75				.m																																											218				3.93				18			101	71.3	17.1					3.63							2.81							6.69							6.64				.m																																											386
SUB231121	Atopic	CSLRA	1.0	expected	150782	b	218				1.95				122			290	239	386					4.06	1.61						6.35							17.4	150	38.9					5.38	3.89			.m																																											218				3.02	6.28			136			331	288	750					3.82							2.17							10.2	66.2	51.6					4.69	9.06			.m																																											381
SUB231122	Atopic	CSLRA	1.0	expected	157604	b	218								110			116	105	122					1.05							1.46							3.53	5.12						2.93	2.43			.m																																											218								89.4			83.7	99.5	79.1					1.77							1.09							1.39							2.51				.m																																											388
SUB231123	Atopic	CSLRA	1.0	expected	138976	b	218				1				18			45.7	34.3	36.6					1														2.31	7.51						1.54				.m																																											218				1.37				19			54.8	39.1	21.5																			2.24							3.28				.m																																											388
SUB231124	Atopic	CSLRA	1.0	expected	134043	b	206					1.81			315			327	570	33.7						2.02							1.75						1.02	8.73							7.57			.m																																											206					1.63			281			249	450	47.8						1.96							1.35							23.2							9.51			.m																																											352
SUB231125	Atopic	CSLRA	1.0	expected	130656	b	206					1.2			11.1			204	40.9	174													1.53						1.29	1.53							1.02			.m																																											206								6.41			178	38.2	10.8						1.56							1.63						2.2	2.25							2.1			.m																																											350
SUB231126	Atopic	CSLRA	1.0	expected	203721	b	218				1.81				6.78			59.2	27.2	3.18					1.76							5.69							5.84	9.51						3.58				.m																																											218				2.34				6.56			56.6	30.8	7.3					2.01							1.87							3.86							4.71	3.33			.m																																											387
SUB231127	Atopic	CSLRA	1.0	expected	297386	b	218								212			3430	499	4050					1.1														7.69	29.4						2.42				.m																																											218				1.19				215			3140	562	4310																			20.4	33.1	4.63					1.99				.m																																											385
SUB231128	Atopic	CSLRA	1.0	expected	305551	b	218				1.96				32.1			711	106	1620					2.14							2.04							6.71							6.25				.m																																											218				1.98	1.83			36.3			480	106	2890					2.94							1.8							6.17							6.89				.m																																											373
SUB231129	Non-atopic	CSLRA	1.0	expected	295607	b	218				1.59				161			319	107	61.2					1.54							1.69							2.04	6.92						1.74	3.33			.m																																											218				1.31				133			308	101	51.1					1.52							1.54							2.2	7.81						1.13				.m																																											373
SUB231130	Atopic	CSLRA	1.0	expected	238586	b	218				2.43				6.02			28.2	63.9	14.6					2.39							2.76							3.56	3.09						2.35				.m																																											.m																																											.m																																											374
SUB231131	Atopic	CSLRA	1.0	expected	227297	b	218								30.5			52	114	2500																			4.1	10.3						1.96	3.28	2.5		.m																																											218				1.05				40.6			55.3	127	2440																			2.94	15.9	7.18					1.73				.m																																											385
SUB231132	Atopic	CSLRA	1.0	expected	166108	b	220								2.37			49.9	42.2	9430						6.01														4.7							3.28			.m																																											220								4.21			58.6	54.5	10900																				5.99										.m																																											375
SUB231133	Atopic	CSLRA	1.0	expected	250053	b	220								26			751	624	26.6												2.71	3.94						5.28	6.83						10.8	14.9	8		.m																																											220								25.8			870	680	22.6						2.14													5.11	8.24						3.29				.m																																											367
SUB231134	Atopic	CSLRA	1.0	expected	328925	b	220				1.71		2.91		18.2			434	86.8	14.1					24.4							1.77		1.14					232							66.8				.m																																											220				2.89				12.2			398	78	8.97					205							1.72							183							68				.m																																											361
SUB231135	Atopic	CSLRA	1.0	expected	164863	b	220								50.2			4580	1210	78.3																			6.06	21.7	1.82									.m																																											220								15.9			5230	610	79.7																			1.57	1.72							3.2			.m																																											369
SUB231136	Atopic	CSLRA	1.0	expected	254069	b	220											354	279	131																			15	1.82						6.68				.m																																											220											265	289	120																			8.46							5.89				.m																																											355
SUB231137	Atopic	CSLRA	1.0	expected	154844	b	220								20.2			232	301	9710					3.5							62.2							7.43	326	263					2.03	31.1	1.16		.m																																											220								18.4			272	339	8920					128	41.1	16.4					2.83							7.39	269	151					10	85.3	3.54		.m																																											342
SUB231138	Atopic	CSLRA	1.0	expected	203966	b	220				46.2	10.4	8.38					1510	1800	4990					26.5	62.1	111					12.5	94	94.7					10.9	3.88						19.6	40.2	11.8		.m																																											220				42.9	14.8	8.23					1300	1370	6250					20.5	49	37.1					13.1	107	63.6					17.6	15.7	1.56					17.1	25.7	5.94		.m																																											348
SUB231139	Atopic	CSLRA	1.0	expected	235002	b	221				4.7				3.29			1140	239	49.1					5.66							4.56							8.42							6.01				.m																																											221				4.69				3.57			667	280	24.3					6.19							5.05							7.46							3.83				.m																																											347
SUB231140	Atopic	CSLRA	1.0	expected	248134	b	220								53.9			141	76.1	714																														.m																																											220								46.4			141	70.3	628																														.m																																											352
SUB231141	Atopic	CSLRA	1.0	expected	233006	b	227				4.23				116			414	283	184					4.12							3.91							15.4	23.5	13.3					5.07				.m																																											227				5.48				140			396	285	207					4.95							4.95							21.3	11.3						5.44				.m																																											352
SUB231142	Atopic	CSLRA	1.0	expected	280338	b	221				2.46				12.3			93.2	80.2	55.5					2.93							2.6							5.97							3.32				.m																																											221				2.2				11.4			99.3	78.3	54.8					2.53							2.65							6.21							4.33				.m																																											342
SUB231143	Non-atopic	CSLRA	1.0	expected	248022	b	221								114			631	168	110					1.13							1							2.01							2.99				.m																																											221								129			598	217	216					1.5							1							1.25							2.14				.m																																											341
SUB231144	Atopic	CSLRA	1.0	expected	305663	b	227								71.8			150	598	1070									1.57			1.31	1.82	1.53						382	6.6		1.86				17.4	3.19		.m																																											227								61.2			135	551	1340									1.44			1.17	1.4	1.99						292	7.48		2.61				17.6	2.47		.m																																											345
SUB231145	Non-atopic	CSLRA	1.0	expected	245047	b	227								22.4			87.8	250	1080						3.28													4.36	64.5	22.1						9.35	3.55		.m																																											227								21.5			99.4	234	1010																			8.89	56.2	73.4						3.54	31.6		.m																																											344
SUB231146	Atopic	CSLRA	1.0	expected	212066	b	227								3.67			130	111	125						1.17														15.3										.m																																											227								2.56			103	105	75.3																				21.6							2.87			.m																																											354
SUB231147	Non-atopic	CSLRA	1.0	expected	342151	b	228				1.99		2.38		41			32.6	134	509					1.77		2.09					1.52		1.08					1.41		4.23					1.54		1.74		.m																																											228				2.06		1.13		31.4			29.5	120	840					1.4		1.85					1.39		2.09					1.59	1.17	1.56					1.51		2.72		.m																																											364
SUB231148	Atopic	CSLRA	1.0	expected	238810	b	227								5.98			19.7	68	157																				10.6										.m																																											227								3.93			18	69.1	189																											1.23			.m																																											343
SUB231149	Atopic	CSLRA	1.0	expected	234778	b	228				5.91				20.9			312	421	289					1.64		3.12					2.51		3.4					4.24		2.09					2.02		3.06		.m																																											228				6.17				23.3			302	357	389					2.54		1.19					2.18		4.01					3.92	2.18	3.34					1.67		4.18		.m																																											362
SUB231150	Atopic	CSLRA	1.0	expected	250165	b	228				1.16				4.03			906	1700	468												1.14		3.68					3.2		1.79					1.03	8.1	1.91		.m																																											228				1.11		3.46		2.71			1110	1660	551												1.12							2.94	1.97						1.18	1.33	1.68		.m																																											355
SUB231151	Non-atopic	CSLRA	1.0	expected	253065	b	227											27.3	79.7	84.6																														.m																																											227								2.56			31	77.9	92.4																														.m																																											341
SUB231152	Atopic	CSLRA	1.0	expected	156264	b	228				2.47		2.21		13.2			8.4	354	10.7					1.4		3.85							3.73							3.12					1.4		5.87		.m																																											228				2.32		3.96		19			8.4	379	14.2					1.95		2.78					1.01		4.01					1.03		1.31					1.31		4.95		.m																																											351
SUB231153	Non-atopic	CSLRA	1.0	expected	255356	b	227								72.6			478	1500	37.5																				113							2.78			.m																																											227								86			457	2090	40.7																				60.4	1.18									.m																																											340
SUB231154	Non-atopic	CSLRA	1.0	expected	244816	b	227								3.39			11.2	67.5	92.4													1.8	1.57									1.75			1.62	1.55	2.25		.m																																											227								1.73			11.1	53.2	69.8													2.06	1.62					1.26	1.8			1.3			2.05	2.08			.m																																											334
SUB231155	Atopic	CSLRA	1.0	expected	293126	b	227								6.4			24.4	378	401							1.43							2.45																.m																																											.m																																											.m																																											339
SUB231156	Non-atopic	CSLRA	1.0	expected	297540	b	227								6.03			18.1	134	679																														.m																																											227								8.04			21.3	132	1180																				3.16										.m																																											337
SUB231157	Non-atopic	CSLRA	1.0	expected	298871	b	232											1190	823	517									1.22				2.42										1.75			1.8	1.89	1.62		.m																																											232											1110	764	520									2.03				2.45	1.78					1.01								1.69	1.45		.m																																											342
SUB231158	Non-atopic	CSLRA	1.0	expected	264837	b	228	1.38			1.73	2.19	1.19		40.9			195	443	777		1.81			3.13	2.18	2.83		1.13			3.71	1.43	1.24		1.63			10.4	84.4	10.3		1.26			4.75	9.07	3.01		.m																																											228	1.51			1.58	2.02	1.62		40			167	380	550					2.62	1.44						4.06	1.71	1.19		1.22			9.53	67.8	5.39		1.44			4.41	13.7	3.6		.m																																											342
SUB231159	Atopic	CSLRA	1.0	expected	267645	b	228				2.45		1.49		751			1700	1620	369					2.39	13	2.55					1.73		2.5					42	1060	837					9.49	343	324		.m																																											228				1.68		2.09		888			1440	1660	632					2.17	8.58	2.26					2.51		1.85					32.5	1100	1170					4.86	199	41		.m																																											337
SUB231160	Atopic	CSLRA	1.0	expected	293252	b	232				9.59				2.26			46.7	33.9	10.6					34.1	1.3	4.66					21.1		3.96		1.03			42.6		5.02		1.6			29	1.76	2.21		.m																																											232				9.45	1.07	1.1		1.28			50.7	33.2	7.67		1.09			28.9		4.35					15.4		3.96					41.9	1.28	5.29					18.9	2.08	1.01		.m																																											332
SUB231161	Atopic	CSLRA	1.0	expected	250277	b	228	2.81			9.03	23.3	1130					1.06		2.84							1.49					1.09		1.31		2.81			2.36	12.7	27.3		3.45			1.75		5.71		.m																																											228				1.08		1.79		1.73			9.36	24.1	619							2.84							1.62		2.43			2.1	10.9	12		1.94			1.55	1.13	3.73		.m																																											339
SUB231162	Atopic	CSLRA	1.0	expected	271515	b	228	4.32			4.14	1.02	3.96		12.9			95.3	223	2570		3.04			6.21	1.11	4.23		2.89			4.33		4.4		2.74			3.63	23	13.5		4.27			4.26	25.8	19.5		.m																																											228	3.6			3.39	1.06	4.62		11.9			99.9	275	2640		3.14			5.26		5.06		2.59			3.95		3.01		1.73			4.49	39.2	9.34		1.89			2.3	5.18	9.23		.m																																											340
SUB231163	Atopic	CSLRA	1.0	expected	276299	b	232	1.4					1.93		12.1			47.5	11.8	839		1.09				2.1								2.54					1.86	1.85	1.44		2.25			1.09	1.69	2.56		.m																																											232								12.8			45	12.4	1050						1.46	2.46							2.42						1.17	1.44		1.3			2.83	4.2	2.6		.m																																											339
SUB231164	Atopic	CSLRA	1.0	expected	314420	b	240				24.6	1.63			13.6			153	61.2	784					17	1.98						14.8	1.1						71.4	22.9	43.7					28	1.71			.m																																											240				27.4				14.4			152	58.4	82.6					16.4	1.22						16.5	2.26						73.1	19.9	23.3					1.29		28.4		.m																																											339
SUB231165	Atopic	CSLRA	1.0	expected	288728	b	232	1.06			7.37	1.56	78.8		8.21			115	100	4950		1.14				1.79	32.9		1.49				1.28	128					1.52	50.6	1160		1.32				10.4	789		.m																																											232	2.33			5.96	1.16	91.8		8.89			99.4	89.1	4880						1.48	148						1.09	253		1.32				48.1	1160		1.46				5.58	504		.m																																											329
SUB231166	Atopic	CSLRA	1.0	expected	292784	b	240				1.9	1.53			10.9			230	99.1	136					5.12	3.57						3.07	3.45						2.05	5.25	4.26		2.11			10.6	10.9	19.3		.m																																											240				2.31	2.35			10.6			252	99.4	172					6.42	4.36						4.8	2.65						37	11.1	36.7		1.56			9.62	6.95	5.59		.m																																											330
SUB231167	Atopic	CSLRA	1.0	expected	256339	b	240				23.5	15.8	29.7		79.6			1200	1870	2410					14.8	47.4						17.6	17.5						82.3	717	291					22.1	65.6			.m																																											240				14	1.29			99.5			1050	2170	1100					13	57.2						13.7	3.18						76.4	484	189					29.9	177	56.1		.m																																											333
SUB231168	Atopic	CSLRA	1.0	expected	333627	b	241				9.64	1.01			19.4			1110	111	153					9.94	2.16						10.4	1.03						36.1	53.8	64.5					19.3	2			.m																																											241	1.01			8.91	1.21			23.4			962	111	561					9.08	1.27						11.3	1						52.1	39.1	21.6					15.6	2.07			.m																																											309
SUB231169	Non-atopic	CSLRA	1.0	expected	431271	b	241	2.51				1.41			7.38			150	96.8	747					12.3	1.45			2.34			9.4	1.41			2.05			11.5	21.5	39.9		2.2			5.41	2.67	1.69		.m																																											241	2.93				1.26			9.71			183	109	810		2.38			17.4	1.3	1.59		2.79			9.89	1.45			2.42			12.4	39	17.7					5.54	2.43	2.78		.m																																											292
SUB231170	Non-atopic	CSLRA	1.0	expected	417650	b	241	2.42				1.31			140			1440	313	12000		2.14			5.09	1.58	3.26		1.89				1.25			2.63			29	25.2	39		2.29			7.92	10.8	38.8		.m																																											241	2.25				1.45			105			1500	236	8440		2.01			1.8	1.21			2.08			1.82	1.43						17.8	17.8	32.1		2.14			9.21	4.96	62.6		.m																																											290
SUB231171	Non-atopic	CSLRA	1.0	expected	438425	b	244				43.7	6.28			4.1			225	1540	1060					26	11.6						28.6	9.13	1.48					35.7	46	106					22.8	14.1	15.4		.m																																											244				49.5	16.4	12.7		4.42			178	916	594					26	30.5	8.25					21.6	3.02						27.6	34.8	59.6					25.3	12.6	5.8		.m																																											220
SUB231172	Non-atopic	CSLRA	1.0	expected	446597	b	244				3.54				2.99			191	20.8	337					9.34	10.4	2.33					4.18	2.15						28	46.7	23.6					22.4	31.8	26.6		.m																																											244				2.94				2.33			223	17.6	480					8.57	16.3	5.08					3.78	1.11						29.6	55.8	45.9					28.3	63.6	43.4		.m																																											218
SUB231173	Atopic	CSLRA	1.0	expected	5807	b	67				7.71			731.52	8.39			202.32	75.27	124.68															1219.48				11.42	8.46		989.69				6.69		25.55	1053.01	67				7.36		20.38	730.91	6.47			213.56	77.77	125.51														3.29	1380.63				11.87	8.35	18.65	1004.06				6.33		2.84	1093.44	67				7.2		9.51	859.69	7.82			116.69	42.3	78.03	12.85														781.38				10.62			1742.54				6.82		2.84	1477.12	67				6.99		16.92	736.37	7.19			119.09	43.28	81.38															781.99				9.5			1524.65				5.9			1325.76	148
SUB231174	Atopic	CSLRA	1.0	expected	8159	b	67							219.25	41.93			164.84	230.94	9239														1.94	461.83					18.48	190.66	123.9						17.35	586.52	67							187.9	33.53			176.48	216.67	5001															482.94					17.36	155.27	107.47						4.64	533.54	67							174.3	36.58			138.92	225.44	9886														29.84	468.47					32.86	239.79	117.09						18.22	439.49	67						8.18	197.56	34.59			125.55	209.02	5001														1.02	354.51					29.87	214.44	127.28						11.7	404.99	135
SUB231175	Atopic	CSLRA	1.0	expected	15651	b	68							117.9	15.09			129.77	243.84	100.73	33.82													18.26	308.09						13.95	363.66							460.12	68							173.45	8.63			121.61	240.71	100.73	3.53														340.13							488.78							532.74	68							95.72	11.36			141.05	268.47	124.37	31.73														371.53							464.89							490.38	68						2.58	104.56	13.88			145.47	257.23	141.31	38.73														358.95							373.1						10.05	539.95	125
SUB231176	Atopic	CSLRA	1.0	expected	15312	b	68							42.96	19.42			314.68	60.66	93.24															4.16							17.31								68							15.96	20.84			326.35	57.13	104.47															59.35															.m																																											.m																																											123
SUB231177	Atopic	CSLRA	1.0	expected	11665	b	77							46.12	14.85			54.27	161.24	1127.78															77.67							98.99							148.15	77							57.47	13.78			50.25	145.31	1086.18	13.92														119.87							116.73							153.39	77							81.3	15.08			47.51	126.44	849.33															97.95					34.33	14.99								176.52	77							59.54	18.41			50.08	134.24	922.29															115.69					33.53		14.42							164.42	120
SUB231178	Atopic	CSLRA	1.0	expected	7711	b	76							70.41				46.29	99.48	770.2	18.93												75.05	25.78	79.61					59.13	11.34								59.1	76						4.41	74.66				50.38	105.55	773.12	10.52												72.54	27.42	82.44					57.07	17.7							7.84	27.37	76						3.47	44.99	4.03			49.07	119.1	783.84													24.47	3.66	89.52				5.92	198.49	64.23								43.58	76						2.91	49.22				42.07	108.64	680													25.09	3.47	54.87					188.13	60.83	43.58							20.34	120
SUB231179	Atopic	CSLRA	1.0	expected	7263	b	76							200.3	8.7			78.71	124.37	364.29														0.41	186.06						2.91	287.35							257.34	76						5.16	218.82	5.55			83.3	115.52	346.17														0.24	201.72						1.82	304.52						1.46	238.79	76						4.41	181.79	11.34			91.54	138.12	381.06	11.92													4.03	220.25					12.38	27.01	235.22							188.91	76							198.16	10.61			96.94	134.09	362.19														4.97	194.6					13.38	24.97	238.79							263.77	114
SUB231180	Atopic	CSLRA	1.0	expected	13266	b	88								9.34			115.34	243.69	2503.66																														88							11.81	11.65			105.77	206.6	2282.9	17.85																													89								10.19			113.1	323.12	3653.89														11.57																89								9.39			103.27	305.85	3567.78	15.71													1.7														23.5		162
SUB231181	Atopic	CSLRA	1.0	expected	31905	b	99b						23.83		215.84			406.87	706.72	4127													32.27	13.02							0.47							48.02		.m																																											99b								176.11			313.85	682.52	4319													17.73	41.38						21.85	49.12							68.07		.m																																											214
SUB231182	Atopic	CSLRA	1.0	expected	28211	b	100								14.95			137.74	176.53	2820.82																														.m																																											100					3.99			12.28			105.82	155.86	545.05													6.1								12.23					7.11	8.1			.m																																											203
SUB231183	Atopic	CSLRA	1.0	expected	135689	b	164								60			815	544	143													1.28						3.16	7.7						1.58		6.85		.m																																											164				1.17				63.5			813	540	91													2.15						2.77	3.72						1.33	1.21			.m																																											514
SUB231184	Atopic	CSLRA	1.0	expected	27251	b	100						11.95		26.22			107.16	232.93	9689													11.97							25.37	17.99					10.43				.m																																											100					5.51			28.15			108.72	229.27	10794.2														11.38					13.62	15.44						14.7	7.12			.m																																											184
SUB231185	Atopic	CSLRA	1.0	expected	135894	b	163				1.12		4.39		8.82			92.7	270	21900					1.25	81.3	5.41						33.4	2.38					5.83	4.04	16.2						6.26	20.4		.m																																											163					3.64	16.5		9.34			78.3	266	17000					1.07	82.6						1.42	62.4	12.2					3.74	6.1	11.1					2.21	5.34	10.9		.m																																											495
SUB231186	Atopic	CSLRA	1.0	expected	26126	b	100						12.23		44.67			316.73	1020.04	23353						10							66.18	16.55					11.6	22.06	13.38						10			.m																																											100								41.52			293.27	720.7	14185						33.06	15.68						50.54	19.16					8.44	43.06								16.55		.m																																											168
SUB231187	Atopic	CSLRA	1.0	expected	26915	b	100								23.99			169.79	110.79	5751.2						4.64																					5.51			.m																																											100								20.61			202.28	115.41	5751.2													6.1																	.m																																											151
SUB231188	Atopic	CSLRA	1.0	expected	44365	b	118								52.41			851.84	761.85	12173																			15.4							17.17				.m																																											118								49.39			846.56	644.58	6972							5.81												19.8							29.92	10.14			.m																																											200
SUB231189	Atopic	CSLRA	1.0	expected	47942	b	118								16.66			919.06	843.63	359.31																			11.57							8.54				.m																																											118								20.51			981.49	870.69	342.48																			8.29							10.67				.m																																											189
SUB231190	Atopic	CSLRA	1.0	expected	27027	b	128								11.02			20	118.24	3535.04																			6.4		1.05									.m																																											128								10.96			15.94	89.18	3209.62																			6.85											.m																																											217
SUB231191	Atopic	CSLRA	1.0	expected	28035	b	118						4.01		103.94			705.52	1258.81	1860.55														3.6					10.85	32.82						16.63		8.47		.m																																											118								116.1			852.88	1274.53	3617.64					8.16							8.11																		.m																																											170
SUB231192	Atopic	CSLRA	1.0	expected	31203	b	118											282.18	61.27	21.78																				12.16										.m																																											118											296.81	49.72	15.3																				70.64										.m																																											158
SUB231193	Atopic	CSLRA	1.0	expected	74994	b	119											3663.19	1474.56	29400																			16.91	214.4							92.68	94.5		.m																																											119											3063.38	1629.5	39200																			19.36	166.14	44.44					11.33				.m																																											148
SUB231194	Atopic	CSLRA	1.0	expected	79374	b	119						6.09		24.37			1393.2	1304.14	8613																			26.42							14.45				.m																																											119								26.7			1501.55	1250.77	8900																			15.38	7.35	12.06					8.06				.m																																											142
SUB231195	Atopic	CSLRA	1.0	expected	79638	b	119						10.17		88.68			205.84	689.92	10699						21.13													1.07	226.57	170.78						55.18	92.89		.m																																											119								91.91			132.02	580.64	7296						12.27								7.33						151.19	87.54									.m																																											138
SUB231196	Atopic	CSLRA	1.0	expected	79286	b	119																											15.48																.m																																											119																																											.m																																											137
SUB231197	Atopic	CSLRA	1.0	expected	80342	b	119								58.14			105.1	553.66	19313							21.96												42.31	31.51	7.33					25.21				.m																																											119								71.05			133.7	638.1	21820							5.65												27.25							23.44				.m																																											132
SUB231198	Atopic	CSLRA	1.0	expected	79726	b	128											318.14	482.37	4287.6						6.73														33.37										.m																																											128											374.04	576.19	2699.4						7.47														32.81							7.44			.m																																											160
SUB231199	Atopic	CSLRA	1.0	expected	79924	b	128								18.04			521.04	444.27	3606.41																				20.38										.m																																											128								18.34			500.17	431.01	4610.69																				27.99										.m																																											142
SUB231200	Atopic	CSLRA	1.0	expected	96556	b	147				2.23				70.5			340	1670	442												1.65							2.73							2.04				.m																																											147				1.49				70.7			532	1410	255					1.76							1.6							3.2							1.72				.m																																											265
SUB231201	Atopic	CSLRA	1.0	expected	79462	b	147				5.9				39.7			332	648	5750					4.01	8.97						2.2							10.1	386	31					3.57	43.7			.m																																											147				5.6				30.6			216	410	5070					2.83	45.6						1.81							23.6	197	16.1					7.15	16.8			.m																																											253
SUB231202	Atopic	CSLRA	1.0	expected	97891	b	147				1.23				269			730	1660	914					1.12														4.37	6.82						1.76				.m																																											147				1.18				283			572	1340	1040												1.51							6.59	7.08						1.69				.m																																											252
SUB231203	Atopic	CSLRA	1.0	expected	80672	b	147				1.12				28.5			559	263	526												1.34							4.03	7.72						2.16				.m																																											147				1.58				26.5			527	271	1160																			1.76							1.65	5.45			.m																																											247
SUB231204	Atopic	CSLRA	1.0	expected	80122	b	159	1.33				3	12.3		25.2			176	128	504		1.32				2.02	7.83						2.54	7.99					1.35	5.19	10.5		1.06				2.31	8.15		.m																																											159					2.31	5.51		18.9			143	99.2	920		1.05				1.09	11.7						1.73	17.8					1.78	3.58	10.1		1.05				1.33	8.15		.m																																											304
SUB231205	Atopic	CSLRA	1.0	expected	92101	b	159	1.04				2.19			29.8			81.1	121	7220		1.25			4.08	2.08	11		1.01			7.18	1.92	2.12					14.1	4.74	9.74		1.18			10.2	2.21	4.16		.m																																											159					1.63	2.41		30.6			95.5	123	10400		1.05			2.91	2.54	4.16					6.01	2.1	8.31		1.03			13.7	10.2						13.3	2.77			.m																																											304
SUB231206	Atopic	CSLRA	1.0	expected	80232	b	159				7.27	1.24	2.12		5.39			1230	550	1360					8.52	3.14	8.31					10.7	2.35			1.4			17.8	43.4	22.1		1.55			10.5	7.74	18.1		.m																																											159	1.11			2.32	3.1	4.6		4.33			779	687	1500		1.06			9.1	1.96	7.36		1.06			11.4	2.83	2.99		1.74			20	6.3	15.4		1.56			11.7	3.91	12.2		.m																																											294
SUB231207	Atopic	CSLRA	1.0	expected	109366	b	159	1.41			3.84	3.61	16.4		9			801	838	576		1.48			13.2	4.07	19.4		1.44			14.2	1.99	18.1		1.95			11.9	62.6	38.2		1.6			9	18.2	28.2		.m																																											159	1.4			6.22	1.84	20.4		14.3			990	925	535		1.64			12.5	2.61	18.8		1.15			20.1		25.1		1.62			18.1	42.3	39		2.03			13.7	2.98	23.1		.m																																											294
SUB231208	Atopic	CSLRA	1.0	expected	99981	b	159	1.32			11.8	3.57	27.5		90.1			489	448	202		1.35			29.4	3.82	27.2		1.44			17.9	2.07	24.8		1.66			38.9	29.2	30.2		2.42			33.4	3.38	27.7		.m																																											159	1.23			4.75	1.58	23.1		96.1			346	430	257		2			19.6	5.56	35.3		1.21			13.7	2.15	25		2.05			20.3	3.63	27.8		1.5			22	3.36	27.8		.m																																											293
SUB231209	Atopic	CSLRA	1.0	expected	109476	b	159	1.33				1.29	34.9		15.4			599	746	44400		1.29			1.53	2.63	38.3		1.39			2.55	2.07	25.8		1.75			2.26	598	96.5		1.31			3.61	4.14	26.8		.m																																											159	1.05				2.86	38.3		13.4			417	636	45100		1.48			2.63	3.13	24.8		1.15			4.61	2.98	27.8		1.29			3.63	373	70.3		1.32			6.09	2.38	38.7		.m																																											283
SUB231210	Atopic	CSLRA	1.0	expected	92904	b	164	1.21			1.82	1.28			138			736	1520	440					4.04							1.78	2.17						12.7	31.4						20.9	3.34			.m																																											164				1.48	1.38			147			840	1660	179					4.08	1.89						1.11	1.76	11.6					16.8	9.01						10.8				.m																																											303
SUB231211	Atopic	CSLRA	1.0	expected	80452	b	164				1.31	1.61	8.7		39.5			392	405	2370						6.61							3.72						5.21	25.2						1.33				.m																																											164				1.33				46.5			363	469	2710						4.65							5.51						4.68	1.63						3.53				.m																																											302
SUB231212	Atopic	CSLRA	1.0	expected	98908	b	164				2.73				44.3			369	302	21700						3.61							1.56						5.86	15.7						1.83	3.63			.m																																											164				2.44				65			339	397	21900		1.71				1.19						1.7	2.54						6.13	106	12.8					2.48	4.56			.m																																											293
SUB231213	Atopic	CSLRA	1.0	expected	90828	b	164								32.9			107	230	9320						1.26	8.1					1.14	1.03						2.12	4.21			1.49			2.31	18.6			.m																																											164								24.1			94.6	206	8850						1.43						1.35	1.99																	.m																																											282
SUB231214	Atopic	CSLRA	1.0	expected	125172	b	164				2.77	1.09			7.19			4490	451	1000					3.96							6.11							29.7	210	106					9.41	6.41			.m																																											164				1.14	2.46			9.21			8850	530	1160					3.78							4.31							8.45	83.2	27					5.54				.m																																											278
SUB231215	Atopic	CSLRA	1.0	expected	123929	b	164	2.45			3.26	1.19			41.8			214	313	10900						1.79										2.95			13.8	14.7	52		4.91			3.47	2.58	13.3		.m																																											164				1.27	1.91	18.3		39.2			206	346	6700													2.43						6.35	6.85	28.6		2.95			2.17	1.03	42.2		.m																																											275
SUB231216	Atopic	CSLRA	1.0	expected	133090	b	179				1.64		30.8		23.9			98.4	145	3290						18.6	477						15.9	42.6					4.59	335	3470					3.57		28.6		.m																																											179				1.25		21		16.5			36.8	66.6	2330																														.m																																											345
SUB231217	Atopic	CSLRA	1.0	expected	131589	b	179						11.4		5.32			1730	1840	974					7.61		3.83					3.63		15.4					21.4	54.1	22.3					13.9	4.95	45.3		.m																																											179				2.9		14		6.25			2000	1550	610					8.68		14.5					3.77		22.1					14.3	3.66	11.4					12.1		35.7		.m																																											342
SUB231218	Atopic	CSLRA	1.0	expected	105262	b	179				2.46		27.8					636	980	3000					1.78		3.25					2.21		22.1					67.9	77.8	123					4.75	13	32.9		.m																																											179				3.11		31.7					372	502	4910					1.64		13.4					4.81		6.52					16.4	25.6	55.9					3.81		15.7		.m																																											342
SUB231219	Atopic	CSLRA	1.0	expected	110063	b	179				3.12		19		5.51			331	5080	1190					2.6	37.8	27.4					5.25	5.86	18.4					7.77	330	97.1					3.8	121	35.7		.m																																											179				4.63		33.1		3.61			212	6760	419					3.56	90.1	21.9					4.02	2.64	38					11.2	323	65									.m																																											342
SUB231220	Atopic	CSLRA	1.0	expected	125971	b	179						21.2		36.1			354	606	37					4.84		10.8					3.11		9.85					7.91		20.2					15.1		21.9		.m																																											179						20.4		11			83.8	440	38.9																														.m																																											337
SUB231221	Atopic	CSLRA	1.0	expected	135193	b	184	1										3.52				1.01			1.36				1.12			2.93							1.19				1.24			1.27				.m																																											184	1.21			1.75		3.14		1.27			4.77		12.7		1.63			1.58		9.39					2.61				1			1.5				1.33			1.5		18.4		.m																																											357
SUB231222	Atopic	CSLRA	1.0	expected	109256	b	179						29		12.9			62.7	170	291					1.55		31.3					15	10.1	63.1						122	44.4					2.66		47.4		.m																																											179						14.5		22.5			82.6	179	609						3.47	43.5					2.42	3.64	5.59						41.3								24		.m																																											330
SUB231223	Atopic	CSLRA	1.0	expected	116393	b	179				1.13		17.5		123			256	196	3130					3.15		34.8					1.91		24.6					4.16	20.3	13.7					5.2		38.7		.m																																											179				6.46		23.8		74			309	289	3190					4.75		40							5.33					5.79	67.3	20.1					4.83	8.44	24		.m																																											324
SUB231224	Atopic	CSLRA	1.0	expected	126464	b	185				5.01				9.47			58.2	192	18.3					34.2							16.2							30.2							23.9				.m																																											185				4.86		4.86		12.9			76	271	123					30		18.3					13																		.m																																											343
SUB231225	Atopic	CSLRA	1.0	expected	124627	b	185						20.7		3.26			283	1670	6170												3.08		148							29.9							56.8		.m																																											.m																																											.m																																											341
SUB231226	Atopic	CSLRA	1.0	expected	106961	b	185						8.15		3.29			1110	2300	2620					236	92.4	137					11.9		19.5					47.3		51.3					53.4		27.6		.m																																											185								8.12			1230	2410	4160					21.8		10.6					7.86		39					35.3	15.8	71.8					42.7		37.3		.m																																											335
SUB231227	Atopic	CSLRA	1.0	expected	137497	b	185						23.6					1920	686	31500						16.9								33.4					6.2	153	111					3.87		29.4		.m																																											185				1.63		44.6					1900	676	26100						18.7	27.6							20.7						135	200					3.87		30.5		.m																																											335
SUB231228	Atopic	CSLRA	1.0	expected	106623	b	185						42.4		42.8			213	318	898							36.8							10.6							11.2							41.3		.m																																											185						14.8		26.2			133	198	670							41.9							9.39						7.91	19.5							27.1		.m																																											334
SUB231229	Atopic	CSLRA	1.0	expected	106396	b	185						41.3		11.5			40.9	88.8	123							31.1							29.9						25.9	40.2							25.3		.m																																											185								18.4			79.2	134	165							24.8							16.6							34.5							2.11		.m																																											333
SUB231230	Atopic	CSLRA	1.0	expected	105821	b	185						25.3		11.3			73.6	111	595														37.9							19.5							28.8		.m																																											185						21.3		5.58			24	244	609							8.15							51.3					1.74		34.5							27.1		.m																																											332
SUB231231	Atopic	CSLRA	1.0	expected	117872	b	185				5.45		27.6		9.8			65.9	64.4	234							24.8							21.9					5.31		27.6					2.84		18.3		.m																																											185				4.1		26.5		11.7			86.8	71.9	331					1.85		92.6					1.74		32.2					5.86		52.4					8.05		64.9		.m																																											331
SUB231232	Atopic	CSLRA	1.0	expected	102599	b	185						29.9		16.1			137	192	267					1.74		33.4							23.6					7.09		32.2					9.93		14.8		.m																																											185						44.1		14.8			130	171	351					3.52		24.2					2.32		26.5					11.1		20.1					9.15		41.9		.m																																											330
SUB231233	Atopic	CSLRA	1.0	expected	137951	b	186											150	488	21000																														.m																																											186											105	513	24300																												6.37		.m																																											333
SUB231234	Atopic	CSLRA	1.0	expected	144188	b	186								46.8			806	2530	913																					22.3							5.09		.m																																											186								75.6			1590	4460	1570																					27.1							35.8		.m																																											333
SUB231235	Atopic	CSLRA	1.0	expected	137165	b	208					1.29	6.77					621	4400	3390						18	7.56						6.67	9.01					1.06	157	11.5					1.02	254	30.9		.m																																											208					2.03	7.53					738	3200	3890					1.14	5.75	8.59					1.04	3.74	4.17					1.5	338	104					1.07	11.3	9.96		.m																																											454
SUB231236	Atopic	CSLRA	1.0	expected	138061	b	185						17.8		123			202	810	678						28.5	35.6							43.5						151	95.7						41.5	86.4		.m																																											185						35.6		91.2			171	387	997						12.7	56.2							61.1					1.95	141	63.3					3.2	127	117		.m																																											329
SUB231237	Atopic	CSLRA	1.0	expected	102379	b	208					1.34	6.89		14.4			73.8	385	1170					1.03	2.78	11.7						3.74	11.8					7.13	2.19	8.62					1.13	1.22	10.1		.m																																											208					1.67	7.66		15.6			79.9	430	1030					1.16	2.64	10.1						2.15	11					3.39	1.59	8.36					2.24	1.23	8.2		.m																																											442
SUB231238	Atopic	CSLRA	1.0	expected	140699	b	208					1.43	8.43		26.9			5200	170	60.6					1.19	1.86	8.59					1		6.45					2.03	13.7	10.7					4.82	10.1	7.79		.m																																											208				1.03	1.27	8.23		37.1			3690	178	63.7					1.18	1.59	6.89							8.14					5.02	1.73	9.11					1.08		5.61		.m																																											431
SUB231239	Atopic	CSLRA	1.0	expected	131956	b	208				1.2		3.92		4.84			67.9	142	8890					1.6	2.25	8.01					1.37	2.83	6.93					5.11	35.9	8.62					4.89	2.86	6.39		.m																																											208				1.05	1.96	7.59		6.05			67.9	150	6580					1.58	2.73	8.23					1.79	2.07	5.21					8.61	104	11.1					5.02	2.39	3.04		.m																																											426
SUB231240	Atopic	CSLRA	1.0	expected	137275	b	208				1.32	1.98	5.7		83.2			589	544	129					1.02	5.56	7.72					1	1.54	5.02					11	828	271					1.48	10.4	7.21		.m																																											208				1.04	1.4	9.34		122			1100	633	2960						6.15	7.91					1.11	1.53	6.02					8.79	763	137					3.57	23.3	16.5		.m																																											425
SUB231241	Atopic	CSLRA	1.0	expected	157376	b	208				1.21	1.44	8.2		9.02			106	299	2980					2.07	1.59	12.6					1.06	3.71	8.56					5.07	5.85	11.3					4.16	3.2	8.27		.m																																											208						5.21		6.66			106	262	2890					1.79	2.46	9.34						15.5	11.9					8.42	8.54	9.7					4.17	1.97	8.65		.m																																											421
SUB231242	Atopic	CSLRA	1.0	expected	221433	b	195					1.45	3.61		287			555	796	916						1.33	4.78						1.19	4.74					23.3	10.7	5.1					5.78	2.05	5.86		.m																																											195								308			626	808	796						1.73	7.96						1.47	6.27					13.6	9.78	5.62					4.33	2.58	6.63		.m																																											338
SUB231243	Atopic	CSLRA	1.0	expected	144527	b	195					1.55	6.11		9.95			57.4	253	5980						1.34	7.4						1.37	6.15						80.1	11.6						3.56	7.72		.m																																											195					1.3	5.14		11.8			35.4	236	4050						1.52	7.15						1.48	6.27						20.3	5.5						1.45	2.47		.m																																											337
SUB231244	Atopic	CSLRA	1.0	expected	132295	b	195					1.38			64.6			286	346	5180					1.58	1.6	6.71						1.4	3.93					34.2	33.2	13.6					17.5	18.4	10.1		.m																																											195					1.33	1.96		69.4			286	325	3510					2.43	1.79	6.11						1.34	4.38					13.9	19.9	49.2					11.8	1.82	2.22		.m																																											338
SUB231245	Atopic	CSLRA	1.0	expected	85898	b	123											33.25	127.61	144.29														0.58					7.47									5.3		.m																																											123											37.71	134.62	146.69														1.91																.m																																											150
SUB231246	Atopic	CSLRA	1.0	expected	96207	b	195					1.72	3.53		77.2			373	634	671						4.22	3.37						1.95	5.54					3.69	5.49	7.35						1.58	4.9		.m																																											195					1.24	3.17		47			292	728	493						1.64	7.31						1.42	5.54					4.74	3.61	2.55					5.47	1.39	5.58		.m																																											323
SUB231247	Atopic	CSLRA	1.0	expected	114210	b	195					1.07	4.74		39.4			454	420	19300						1.27	7.23						1.51	5.22						2.1	3.77					1.6	3.04	6.75		.m																																											195					1.29	4.58		59.5			612	388	16100						1.56	11.4						1.34	7.44					1.9	6.02	4.1						2.16	8.04		.m																																											323
SUB231248	Atopic	CSLRA	1.0	expected	108461	b	206				73.3	10.8	52		23.7			949	782	2270					28.7	478	537					53.5	1000	764					6.09	520	96.9					5.26	455	92.3		.m																																											206				76.7	13.4	41.1		22.8			959	625	2740						2.95						6.05	74.8	389					8.69	685	149					9.3	314	283		.m																																											373
SUB231249	Atopic	CSLRA	1.0	expected	116283	b	196					1.07			9.13			41	51.7	474						2.68							2.07							1.01							4.84			.m																																											196	1.56				2.18	8.04		26.4			49.7	72.2	1230		1.16				3.54	12.6		1.54				4.01	16.4		1.93			1.75	2.4	6.81		1.75				4.18	23.1		.m																																											315
SUB231250	Atopic	CSLRA	1.0	expected	162729	b	206					1.81			13.5			287	630	686						2.26							1.81						1.37	5.09							2.6			.m																																											206					1.53			15			310	727	516						1.67							2.22						2.61	2.21							2.15			.m																																											373
SUB231251	Atopic	CSLRA	1.0	expected	146724	b	206					1.42						162	1230	489						7.38							1.85							33.3							4.64			.m																																											206					2.05						131	1240	439						2.58							2.12	3.08					1.34	170	6.61						2.39			.m																																											368
SUB231252	Atopic	CSLRA	1.0	expected	264727	b	206					1.82			10.4			60.3	61	903						5.49							1.52							1.89							2.08			.m																																											206					2.01			12.8			79.4	58.3	1280						2.02							1.56							5.16							1.55			.m																																											361
SUB231253	Atopic	CSLRA	1.0	expected	224164	b	206					2.08			53			440	689	1750						14.7							14.1							3.16						2.32	4.32			.m																																											206					1.66			69.5			481	810	1280						27.3							4.6						1.02	2.35							1.64			.m																																											361
SUB231254	Atopic	CSLRA	1.0	expected	157156	b	207								38.3			510	311	88.2																			11.2	52.4	104									.m																																											207						1.88		36.7			464	317	78.3														2.31						2.13										.m																																											363
SUB231255	Atopic	CSLRA	1.0	expected	136004	b	206					1.75			8.58			43.5	126	230						2.93							1.78						3.46	2.28							1.91			.m																																											206					1.55			6.34			46.1	96.7	293					1.31	1.89							1.56						2.84	2.51						2.79	2.17			.m																																											361
SUB231256	Atopic	CSLRA	1.0	expected	136114	b	207						2.31		45.2			46.3	220	122						4.22	1.79													60.7	4.27									.m																																											207					2.01			33.2			32.8	193	136																				69.3	3.72									.m																																											360
SUB231257	Atopic	CSLRA	1.0	expected	132524	b	207											77.9	1730	2050																				117	14.1						3.55			.m																																											207											49.1	1870	1150						2.09														46.9	6.31									.m																																											353
SUB231258	Atopic	CSLRA	1.0	expected	128759	b	218				1.47				22.3			23.7	118	46.9					1.41							1.17							1.73	3.4						1.4				.m																																											218				1.94				24.3			19	116	35.8					1.47							1.49							1.78	17.1										.m																																											395
SUB231259	Atopic	CSLRA	1.0	expected	137731	b	218				2.31				15			150	68	16.2					1.59		4.06					2.35	1.75						3.46							3.65	1.55			.m																																											218				2.31				17.8			148	66.1	21.6					1.61							1.73		2.66					3.37							2.79				.m																																											383
SUB231260	Atopic	CSLRA	1.0	expected	310797	b	218				2.51				15.9			238	403	1460					2.38	10.3						2.04	2.48						7.11	8.14						6.97	1.47			.m																																											218				2.24				25.2			279	440	1700					2.04	5.03						1.77	17.4						7.59	28.8	3.39					7.6	7.19			.m																																											378
SUB231261	Atopic	CSLRA	1.0	expected	207463	b	218				2.32				106			152	308	564					3.07							2.03	2.2						5.56	10.5						4.43	2.62			.m																																											218				2.03	2.55			140			152	359	443					2.76		3.8					1.9							4.92	6.65						4.49	1.98			.m																																											372
SUB231262	Atopic	CSLRA	1.0	expected	142776	b	219											125	925	9600																					1.58					1.11				.m																																											219											118	1090	9790							8.94																1.18							.m																																											374
SUB231263	Atopic	CSLRA	1.0	expected	157723	b	219								6.18			40.3	35.3	124																			3.2							2.21	1.35			.m																																											219								5.24			42.2	37.9	240																			5.55							3.91				.m																																											371
SUB231264	Atopic	CSLRA	1.0	expected	143003	b	221					1.64			7.12			20.2	268	460														2.49					1.9	5.64	6.94						15.6			.m																																											221								9.04			30.9	247	148																			1.22	5.72							6.81			.m																																											369
SUB231265	Atopic	CSLRA	1.0	expected	132066	b	221								7.6			132	92.3	1200													1.8							211	49.4					2.15	28.8	13.1		.m																																											221								6.77			129	77	1210					1.07							1.03	1.23						2.48	24.1	1.58					2.17		1.08		.m																																											357
SUB231266	Atopic	CSLRA	1.0	expected	346697	b	221								2.01			4.06	32.8	91.5						2.04														28.9	1.25						1.28	3.73		.m																																											221						1.32		2.59			4.35	41.9	46.6							1.17													6.72	4.11						7	1.95		.m																																											355
SUB231267	Atopic	CSLRA	1.0	expected	133209	b	224											509	1210	3080					1.08														1.77	131	11.7							2.89		.m																																											224											500	981	2740																			1.29	36.1	1.97									.m																																											362
SUB231268	Atopic	CSLRA	1.0	expected	283698	b	232												4.95	23.5												3.18	1.67																	.m																																											232					1.26							5.47	24.8												1.69								1.07										.m																																											383
SUB231269	Atopic	CSLRA	1.0	expected	157833	b	232								9.97			116	101	1380																				19.7	14.7									.m																																											232								8			128	98.3	440																			2.28	6.98										.m																																											376
SUB231270	Atopic	CSLRA	1.0	expected	276039	b	228	2.69			3.08		4.51		43.7			158	790	34.4		2.84			3.75		5		3.57			2.65		6.04		2.74			4.71	4.49	6.69		3.24			2.5		3.12		.m																																											.m																																											.m																																											370
SUB231271	Atopic	CSLRA	1.0	expected	276780	b	228	3.19			3.03		8.9		4.78			15.2	81.6	1760		2.2			2.64		5		2.79			2.08	1.01	7.5																.m																																											.m																																											.m																																											369
SUB231272	Atopic	CSLRA	1.0	expected	363892	b	232				5.86				6.27			391	130	3420					1.94							1.88							16.6	23.4	310					5.61				.m																																											232				5.35				4.54			365	159	3440					19.7	148	581					1.83							19.6	308	89.9					3.96	2.51			.m																																											365
SUB231273	Atopic	CSLRA	1.0	expected	366184	b	232				1.14		1.61		18			104	373	728																			2.5	32.6	1.74						1.06			.m																																											232								15.4			115	372	877						1.03													3.14	50.2	3						4			.m																																											361
SUB231274	Atopic	CSLRA	1.0	expected	244078	b	228	2.41			4.81	3.06	4.89		7.19			78.9	355	16100		2.49			1.8	14	6.2		2.33			1.72	5.77	5.06		4.37			4.05	178	96		2.94			2.41	52.3	11.1		.m																																											228	2.94			4.66	3.27	6.2		7.74			108	319	14900		2.89			1.73	8.96	6.25		2.23			1.65	13	10.3		2.92			3.34	207	107		2.94			2.27	38.1	9.82		.m																																											358
SUB231275	Atopic	CSLRA	1.0	expected	300159	b	228	4.11			2.64		4.4		4.29			7.94	7.89	3.23		2.76			2.15		3.4		2.38			2.73	1.03	6.58		1.78			7.38	1.21	4.73		3.27			9.89	1.2	6.79		.m																																											228	4.24			2.2		6.36		3.6			7.85	7.97	6.63		2.43			2.52	1.02	4.07		1.86			2.99		5.55		3.04			8.53	1.47	4.18		4.01			10.1	1.21	6.96		.m																																											357
SUB231276	Atopic	CSLRA	1.0	expected	338476	b	228	3.07			3.29		3.51		82.1			143	1470	247		3.12			2.26		6.09		2.79			4.1	1.02	4.45		2.64			5.17	54.1	11.3		2.81			3.1	1.33	7.66		.m																																											228	3.5			3.25		5.22		88.2			106	1240	307		3.47			2.62	2.62	5.22		5.41			4.88	18	9.93		3.68			3.64	1.06	1.91		2.69			2.68	1.02	5.38		.m																																											353
SUB231277	Non-atopic	CSLRA	1.0	expected	311517	b	228	2.33			1.9		5.6		118			440	605	1110		2.66			2.85		4.45		2.79			2.59		3.51		2.69			6.03	87.6	5.55		1.66			1.92	4.66	2.04		.m																																											228	2.54			1.91	1.2	4.18		107			413	573	1610		2.64			1.98		4.51		2.79			2.73		4.51		2.94			8.72	730	15.8		1.41			1.52	8.96	2.56		.m																																											352
SUB231278	Non-atopic	CSLRA	1.0	expected	316451	b	232								10.9			27.7	251	307																				1.03										.m																																											232								10.9			30.5	257	299																				2.02										.m																																											353
SUB231279	Atopic	CSLRA	1.0	expected	356203	b	232								4.39			151	43.2	518																			4.62	9.52	5.92		2.47			1.63	2.1			.m																																											232								4.94			136	41.2	396																1.09			3.57	1.75	2.38		2.33			2.13	1.84	2.65		.m																																											346
SUB231280	Non-atopic	CSLRA	1.0	expected	281074	b	232	1.23				1.9			2.92			28.4	40	3450							1.88							3.56		1.36				140	13.1							3.01		.m																																											232						2.09		2.03			21.5	35.6	2460						1.22	2.93						1.02	2.21						117	10.7									.m																																											343
SUB231281	Atopic	CSLRA	1.0	expected	267991	b	232								4.02			55.9	123	646														1.97						164	16.2									.m																																											232	1.32				1.04	2.38		4.56			71.2	108	3450		1.12				4.49	2.34						1.36							160	19.8		1.48			2.52	1.8	1.01		.m																																											339
SUB231282	Atopic	CSLRA	1.0	expected	292667	b	232						2.85		5.56			103	182	215		1.79					2.21							2.46					2.19	1.79	1.17					3.09	1.99	1.91		.m																																											232						2.82		4.39			98.3	166	265		1.32					2.62							2.13						2.12	2.7					1.89	1.57	3.41		.m																																											329
SUB231283	Atopic	CSLRA	1.0	expected	286875	b	232	1.89					1.93		5.98			160	322	3200		1.09			1.83		3.92		1.32			1.59		2.46		1.12			3.68	1.59	1.71					1.72		2.05		.m																																											232						1.29		5.65			155	329	3480					2.74		2.26					1.07		2.13					5.55	5.07	3.37		1.34			2.33				.m																																											322
SUB231284	Atopic	CSLRA	1.0	expected	363150	b	240					1.68			20.2			32.8	292	1950		1.08				4.37						5.21	1.53						2.91	368	87.6					1.36	8.86			.m																																											240					1.66			22.6			28.6	323	2690		1.3				2.29						3.89	2.28						3.22	390	111						43.9			.m																																											331
SUB231285	Non-atopic	CSLRA	1.0	expected	356654	b	240				3.05	1.37			2.77			99.6	131	14900					5.63	2.23						7.82	1.56						19.2	29.7	6.38					19.9				.m																																											240				2.88				2.67			101	132	8870					4.49	1.44						6.14							17.6	65.6	52.5					12.8	1.73			.m																																											331
SUB231286	Atopic	CSLRA	1.0	expected	301233	b	240					1.71			19			118	136	12400						2.57						4.68							11.9	114	357					3.65	3.37			.m																																											240								13.8			129	118	14100					3.62	1.58						4.11							15	118	254					2.7	6.57	11.6		.m																																											328
SUB231287	Non-atopic	CSLRA	1.0	expected	347688	b	240					1.37			32.8			297	275	295					9.93	1.1						13.6	1.3			2.32			13.5	5.71			3.97			13.6	1.66			.m																																											240								51.5			199	494	362					11.2	1.27						12.4				5.28			14.6	21.9			3.97			19.9	3.81	4.1		.m																																											328
SUB231288	Atopic	CSLRA	1.0	expected	397711	b	240	3.29				3.81	11.4		19.5			187	351	2000		4.15			22.8	78.5	2330																							.m																																											.m																																											.m																																											317
SUB231289	Atopic	CSLRA	1.0	expected	311407	b	240	2.15				2.07			18.7			22.1	345	866		2.29				2.6	3.79		3.42				3																	.m																																											.m																																											.m																																											317
SUB231290	Atopic	CSLRA	1.0	expected	375288	b	240	3.32				1.36	4.26		19.8			69.4	89.7	5370		3.8				5.99			2.35				1.56			2.42				1.78			2.29				2.2			.m																																											240	2.88				3.56			14.4			111	96.7	6420		2.29				2.06							2.34			2.95				1.68	1.73		4.36				1.51			.m																																											313
SUB231291	Atopic	CSLRA	1.0	expected	341370	b	240	3.02			1.39	1.73			78.3			346	484	445		2.95			3.01		2.71					7.84	1.81	2.07		3.15			11.8	19.4	1.9		2.81			12	3.11	2.07		.m																																											240	3.15			4.7	2.18	1.73		57.5			316	427	226		3.63			4.3	1.86	1.21		3.15			10.1	1.73			2.71			13.5	7.19	4.88		2.78			10.9	11	4.57		.m																																											309
SUB231292	Atopic	CSLRA	1.0	expected	418328	b	244								18.5			83.3	95.5	3140																				30.7	210					1.66	9.89			.m																																											244								10.3			91	57.7	4040												1.14							1.09	146	116					1.94				.m																																											316
SUB231293	Atopic	CSLRA	1.0	expected	8047	b	65						7.21	165.34	66.02			162	525.33	1490	15.03												11.48	5.91						20.46										65						0.36	117.83	57.5			133.02	463.35	3869.11													11.34		25.82					18.52								1.84		65							87.12	67.96			171.1	532.32	2166													9.74	1.84	18.16					13.6										65							62.69	55.44			135.51	497.41	4886.41															13.79					14.15										146
SUB231294	Atopic	CSLRA	1.0	expected	62	b	63					9.41		234.52	37.37			81.4	294.1	2126.7													8.82	5.51					4.97	13.86	4.07						8.52	8.27		63	8.34				9.75	33.77	276.04	33.88			81.76	288.67	2015.59													10.42	25.68						16.8	30.34	58.52					9.41	38.29		.m																																											.m																																											174
SUB231295	Atopic	CSLRA	1.0	expected	7847	b	64							1039.38	44.64			69.31	1211.73	1446.97															1266.95					12.72		2950.26						2.88	2768.29	64							1178.99	45.69			71.64	1403.33	1513.47															1392.53					13.54	20.69	3032.3							2749.18	64							1286.24	45.6			80.38	1385.21	1558.1															1499.23					16.99		2086.26							2762.41	64							1317.94	48.5			78.55	1334.27	1583.47															1603.57					17.05	8.49	2109.02							3056.25	148
SUB231296	Atopic	CSLRA	1.0	expected	10195	b	65	3.4						125.78	2.99			31.14	39.05	1640															13.79							19.42								65					9.64		143.27				25.29	34.33	4230.67	21.97																						3.16					7.21		65						14.75	139.61	2.76			27.95	34.33	3010																				22.27	27.95								36.3	65							125.78				24.19	29.71	5001															15.65					21.62	8.49							1.12	13.18	135
SUB231297	Atopic	CSLRA	1.0	expected	10758	b	66							4143	30.39			111.1	213.56	1278.99	19.66													17.27	110.15														20.53	66						6.88	70.27	35.55			117.92	204.42	1317.04														0.16	116.09							7.61						9.48		66						14.15	34.03	34.2			101.73	212.19	1546.44															8147													2.74	29.06	66							57.15	31.43			98.13	199.75	1521.59	36.48														91.48													10	2.21	132
SUB231298	Atopic	CSLRA	1.0	expected	15987	b	66						0.67	17				31.04	188.88	1729.41															32.38					30.68							18.24	8.44	13.36	66							25.69				29.32	185.54	1746.34															34.85					30.3		2.21					16.33		2.21	66							42.14				28.92	177.58	751.09	7.61														17					26.19							10.83	20.92	15.2	66						2.74	95.98	9.73			27.73	176.04	680.43	4.49														58.7					26.72							9.95	6.88		118
SUB231299	Atopic	CSLRA	1.0	expected	16574	b	66						0.67	149.99	30.76			44.17	433.63	3693.12															196.82							7.61						22.48		66						13.11	137.5	37.29			42.73	416.66	3519.18															112.38						4.81									66						16.23	130.13	31.5			33.49	345.64	4362.11	18.78													5.84	120.53													10		66							160.99	32.62			37.85	375.14	4316.47														1.7	159.52													21.44	7.61	118
SUB231300	Atopic	CSLRA	1.0	expected	23959	b	77							50.25				25.83	108.89	1400.14	14.42														50.25					11.36									25.1	77							44.06				25.72	105.06	1425.61	25.61														28.67					8.43									25.61	77							40.98	9.95			21.92	105.52	1660.46															13.41														42.52	77							47.15				22.53	104.48	1721.54															23.06														27.65	114
SUB231301	Atopic	CSLRA	1.0	expected	20649	b	89						8.87		47.81			74.8	603.48	564.3																					15.4							8.87		89							24.84	48.81			74.18	588.19	561.63																												5.2	24.42	89						13.35	40.52	50.91			78.66	653.63	536.37															34.77						13.94							3.32		89						15.99	23.15	47.85			81.51	673.4	534.91														3														5.2		153
SUB231302	Atopic	CSLRA	1.0	expected	26350	b	77							76.11	133.9			150.7	876.44	4987.21															152.34							71.96								77							57.99	106.9			130.94	800.89	4722.45	10.38														135.57							32.77								77							51.28	115.93			120.66	935.64	4946.61	20.51												8.63		83.38							117.78							28.67	77							99.51	135.86			139.01	926.02	4948.39															167.05							111.51							11.39	104
SUB231303	Atopic	CSLRA	1.0	expected	26462	b	77							50.25	16.69			74.23	324.37	994.89															65.23														9.88	77							76.63	19.52			69.13	304.37	982.03	30.21														26.63														17.97	77							64.71	19.48			90.52	342.85	1643.74	36.87														55.41														14.42	77							84.94	15.27			76.66	307.64	1369.36	14.42												13.06		39.44						15.71						8.49			104
SUB231304	Atopic	CSLRA	1.0	expected	27654	b	78							25.11	15.4			306.4	316.85	489.12																			9.61											78							16.06	14.75			270.43	304.58	413.19																			7.22											78								19.11			363.14	354.19	383.22																														78								14.6			330.1	320.15	364.35																														105
SUB231305	Atopic	CSLRA	1.0	expected	29522	b	79							53.83	20.33			60.04	94.9	2983.4															85.07														114.42	79							47.06	19.69			53.84	89.47	2800.1															100.35														119.41	79							77.74	16.92			46.21	104.86	1289.63														8.35	67.21														134.73	79						12.08	110.35	14.47			37.42	99.36	1151.83															31.68														132.86	102
SUB231306	Atopic	CSLRA	1.0	expected	29610	b	79								45.08			465.14	379.42	446.47																														79							32.89	42.27			448.65	360.7	465.06														8.72																79							18.16	35.63			390.37	348.53	442.61														8.53						3.24	7.43									79							13.66	34.48			423.35	374.57	454.43																												10.57		100
SUB231307	Atopic	CSLRA	1.0	expected	32446	b	79							97.07	14			41.48	103.27	2374.38														12.08	114.42						13.4	118.42						7.61	133.8	79							97.07	15.59			37.86	112.56	2369.79															120.4							118.42						11.32	95.41	79							101.43	17.88			57.81	122.64	2994.91															156.79						6.52	156.35							76.47	79							92.04	12.99			38.64	95.09	2642.62															137.05							127.18							41.46	94
SUB231308	Atopic	CSLRA	1.0	expected	27830	b	80						4.71		7.73			12.7	95.76	1036.41																					2.64									80								9.37			17.36	99.64	1061.37																												0.02		80						1.76		9.61			15.23	96.05	1419.75														6.5																80							8.13				15.53	95.21	1315.41														0.02							0.45								8.13	95
SUB231309	Atopic	CSLRA	1.0	expected	34531	b	80						0.02	32.15	61.23			62.47	956.85	1764.86														5.6	39.94						7.25				9.99	8.42	239.06	65.64		80						0.88	92.96	82.94			79.27	970.79	1877.28														3.23	30.55							14.63				9.91	237.29	60.53		.m																																											.m																																											87
SUB231310	Atopic	CSLRA	1.0	expected	33823	b	98a								25.24			44.4	296.01	871.95																														.m																																											98a								22.25			40.78	308.35	1279.11																														.m																																											180
SUB231311	Atopic	CSLRA	1.0	expected	38555	b	98a								289.11			221.02	1948.63	91.77																				22.18										.m																																											98a								287			177.85	1756.5	116.64																				28.34										.m																																											176
SUB231312	Atopic	CSLRA	1.0	expected	42273	b	98a								10.56			52.74	117.01	818.76																			8.01											.m																																											98a				8.72	14.35	38.86		8.93			27.21	123.99	618.66														4.65																.m																																											169
SUB231313	Atopic	CSLRA	1.0	expected	36284	b	98a								18.02			274.55	604.71	8782.8																				41.76							12.19			.m																																											98a								17.32			227.59	610.4	7569.7																				25.82	16.38									.m																																											178
SUB231314	Atopic	CSLRA	1.0	expected	35349	b	98a								18.55			53.65	317.77	827.57													12.9																	.m																																											98a								22.62			53.26	334.27	1192.41													7.91							8.48										.m																																											167
SUB231315	Atopic	CSLRA	1.0	expected	44141	b	99b								18.62			30.49	66.76	1604.13							35.87							18.4							11.95							66.95		.m																																											99b						14.1		19.07			22.95	70.84	1265.64																														.m																																											167
SUB231316	Atopic	CSLRA	1.0	expected	44961	b	99b						73.67		116.78			250.2	277.45	3281.38							58.02							4.56						11.67								81.53		.m																																											99b						30.38		91.98			236.51	252.12	3110.13														15.17						14.11								6.65		.m																																											166
SUB231317	Atopic	CSLRA	1.0	expected	44253	b	99b	4.81					52.46		63.82			611.33	475.77	1617						12	27.1							18.4						12.06	0.47							39.17		.m																																											99b								71.18			757.07	582.03	747							53.57														23.83									.m																																											165
SUB231318	Atopic	CSLRA	1.0	expected	34867	b	99b						3.52		554.91			346.72	782.25	1698.41							4.56							45.8							7.7							19.49		.m																																											99b						49.12		486.03			260.9	645.65	1304.45							39.17							9.82						16	8.76							10.89		.m																																											155
SUB231319	Atopic	CSLRA	1.0	expected	31993	b	99b								55.21			85.33	665.9	188.56							40.27							1.47					7.1											.m																																											99b						6.65		42.66			45.27	474.69	134.76							45.8							4.56							30.38						9.14	15.26		.m																																											152
SUB231320	Atopic	CSLRA	1.0	expected	46418	b	99b								165.47			166.77	705.76	1240														0.47							6.65							17.32		.m																																											99b	4.81					10.89		178.01			184.05	687.15	1923		8.5												30.38							44.69									.m																																											148
SUB231321	Atopic	CSLRA	1.0	expected	31539	b	101						12.01		56.74			193.68	591.9	415.05														9.85							23.22					5.33				.m																																											101						8.22		26.98			110.08	424.35	360.95							28.76							11.74							12.55							20.57		.m																																											153
SUB231322	Atopic	CSLRA	1.0	expected	53694	b	101						11.74		21.26			194.67	1089.85	102.47							13.09							7.4						13.15	7.67							8.22		.m																																											101						12.28		14.57			104.19	752.44	111.86																														.m																																											144
SUB231323	Atopic	CSLRA	1.0	expected	25109	b	116								32.48			86.01	560.2	270.53													11.31																	.m																																											116								28.31			68.65	460.82	294.58						2.69																								.m																																											181
SUB231324	Atopic	CSLRA	1.0	expected	61604	b	116								38.9			181.8	570.03	577.32																														.m																																											116								42.37			154.38	645.1	581.92																														.m																																											180
SUB231325	Atopic	CSLRA	1.0	expected	33026	b	116								189.89			370.57	1582.3	357.94						16.44														74.97	13.23						17.09			.m																																											116								211.23			423.05	1647.68	181.81						12.39														127.33							8.17			.m																																											180
SUB231326	Atopic	CSLRA	1.0	expected	66327	b	116								37.5			151.95	202.37	4226.33						13.65							20.83						10.26	75.26										.m																																											116								43.84			151.9	220.03	4446.91						5.1														18.2										.m																																											168
SUB231327	Atopic	CSLRA	1.0	expected	54726	b	117								8.33			67.03	314.27	171.43																												2.37		.m																																											117								13.28			66.43	348.11	236.09																														.m																																											179
SUB231328	Atopic	CSLRA	1.0	expected	67899	b	117								29.33			149.33	446.45	1984.03																														.m																																											117								34.5			158.51	437.56	1866.28																			6.76											.m																																											175
SUB231329	Atopic	CSLRA	1.0	expected	57337	b	116								10.52			54.64	238.86	31.52																														.m																																											116								12.84			55.13	211.98	41.83																												8.22		.m																																											171
SUB231330	Atopic	CSLRA	1.0	expected	65344	b	117						41.52					18.63	172.2	228.67																														.m																																											117						38.89					16.17	178.65	240.15																														.m																																											164
SUB231331	Atopic	CSLRA	1.0	expected	64710	b	117						6.83					54.6	259.36	15591																														.m																																											117						10.62					44.05	269.39	11589																														.m																																											159
SUB231332	Atopic	CSLRA	1.0	expected	67519	b	117								6.1			219.92	167.37	19.53																														.m																																											117								7.65			273.28	170	18.9																														.m																																											155
SUB231333	Atopic	CSLRA	1.0	expected	81390	b	118								102.52			221.24	1027.99	2640.94																			35.1							19.6	16.3			.m																																											118								110.1			254.92	1095.56	2798.66							12.87												30.47							13.93				.m																																											144
SUB231334	Atopic	CSLRA	1.0	expected	81793	b	118								16.26			260.78	322.16	371.43																											13.5			.m																																											118								11.57			207.47	316.96	219.88																														.m																																											142
SUB231335	Atopic	CSLRA	1.0	expected	82761	b	118								84.47			259.81	1062.87	1253.64						9.5							9.82							23.89	4.42									.m																																											118								25.01			133.89	508.65	2223.67						15.38							21.19							17.3	5.81									.m																																											142
SUB231336	Atopic	CSLRA	1.0	expected	88848	b	117								36.42			409.82	695.89	303																														.m																																											.m																																											.m																																											151
SUB231337	Atopic	CSLRA	1.0	expected	82057	b	123								77.78			338.68	554.18	688.61						10.11																					8.05	0.58		.m																																											123								84.22			297.74	561.81	877.83						7.84	4.7												8.66	15.08	8.81									.m																																											151
SUB231338	Atopic	CSLRA	1.0	expected	83729	b	123								29.49			76.77	262.36	5747							12.51														7.07					7.9	14.99			.m																																											123								28.56			84.04	260.98	5123														4.7					6.51	17.6						10.44				.m																																											145
SUB231339	Atopic	CSLRA	1.0	expected	81705	b	123								9.85			248.89	314.77	280.6													6.76							18.7	9.1									.m																																											123								11.94			181.31	319.75	566.67						6.87								1.91						6.32										.m																																											145
SUB231340	Atopic	CSLRA	1.0	expected	81969	b	123				6.81		5.3					42.6	314.56	9.39																			7.23		7.07						7.94	5		.m																																											123				9.13		8.81		6.35			47.54	395.33	0.58														6.48					7.02		16.97					8.91	9.6	9.39		.m																																											146
SUB231341	Atopic	CSLRA	1.0	expected	81881	b	123								12.56			116.69	222.05	8919																			10.16	10.16	10.25									.m																																											123								17.79			111.97	222.64	8637						6.32													9.93		6.48									.m																																											142
SUB231342	Atopic	CSLRA	1.0	expected	96667	b	123								12.05			183.59	485.74	2395.55														0.93							3.79							2.55		.m																																											123								11.99			122.16	477.96	1199.4														1.59														2.86		.m																																											140
SUB231343	Atopic	CSLRA	1.0	expected	101801	b	124								5.6			104.72	306.94	2795.1					8.17							9.42							20.19		3.11					14.34		16.47		.m																																											124								4.52			109.56	308.95	2541.11					7.47							8.17		2.42					21.99		7.07					15.45				.m																																											135
SUB231344	Atopic	CSLRA	1.0	expected	101456	b	124								59.78			119.87	402.94	100.24																												1.37		.m																																											124						7.71		57.93			120.36	390.45	126.74																														.m																																											135
SUB231345	Atopic	CSLRA	1.0	expected	83377	b	124								44.76			605.1	405.49	664.19						7.64	10.57																					1.01		.m																																											124								36.68			679.58	336.41	426.57						10.1							3.59														5.62	4.12		.m																																											131
SUB231346	Atopic	CSLRA	1.0	expected	104548	b	124								24.43			695.71	522.88	230.47						1.07														22.15	10.89									.m																																											124								20.46			669.05	545.99	257.65						12.69														16.69										.m																																											133
SUB231347	Atopic	CSLRA	1.0	expected	106851	b	126																											9.16						21.77										.m																																											126																				6.19							39.37						18.91								4.17		.m																																											126
SUB231348	Atopic	CSLRA	1.0	expected	106286	b	126								33.7			124.57	410.1	10523														2.61					6.34		12.56									.m																																											126						2.08		32.12			135.81	409.39	13844														0.99																.m																																											122
SUB231349	Atopic	CSLRA	1.0	expected	96889	b	126						3.13		12.43			21.26	373.66	2532.73																					36.67									.m																																											126						9.16		14.41			36.87	242.49	1669.83																														.m																																											125
SUB231350	Atopic	CSLRA	1.0	expected	105019	b	128								50.75			45.56	827.44	248.08																			15.09											.m																																											128								49.14			45.04	693.37	193.18												6.74							14.59							9.48				.m																																											124
SUB231351	Atopic	CSLRA	1.0	expected	103990	b	126								157.25			563.59	988.24	645.68																				17.96								0.42		.m																																											126								161.06			675.11	992.16	872.81																				19.96	3.13									.m																																											126
SUB231352	Atopic	CSLRA	1.0	expected	83025	b	126								10.75			258.3	467.56	38.02																														.m																																											126								14.41			236.19	517.78	43.41																														.m																																											112
SUB231353	Atopic	CSLRA	1.0	expected	83201	b	128						85.46					58.85	175.57	25429						6.73	550.18						14.16	500.23						19.96	1425.17						52.55	3549.97		.m																																											128						133.98					40.99	138.59	24649						8.39	369.46																							.m																																											118
SUB231354	Atopic	CSLRA	1.0	expected	103078	b	128											56.32	83.75	2592.51																														.m																																											128											66.23	79.82	2468.86																				10.11										.m																																											118
SUB231355	Atopic	CSLRA	1.0	expected	83641	b	128								48.02			281.26	649.73	1798.08																				17.97										.m																																											128								45.57			309.6	673.9	1410.15					36.04	22.33	984.01						6.77							13.6										.m																																											116
SUB231356	Atopic	CSLRA	1.0	expected	97451	b	128								28.18			62.61	618	904.38													9.96						7.52	216.32										.m																																											128								26.64			73.23	622.65	1183.99						25.19																								.m																																											118
SUB231358	Atopic	CSLRA	1.0	expected	82497	b	148				2.45		2.68		11.2			53.9	205	223					1.73		4.31					2.72		1.03					2.76	7.16	3.28					2.11		2.94		.m																																											148				2.31		4.74		10			59	185	277					2.69	1.25	1.32							1.92					1.38							3.5	2.56			.m																																											242
SUB231359	Atopic	CSLRA	1.0	expected	94409	b	148				2.25		3.02		60.4			253	535	819					8.65							10.2		1.03					8.72							5.26				.m																																											148				2.04		2.94		44.8			207	449	640					6.83							8.07	1.75	1.83					11.1	3.09	5.53					7.25				.m																																											240
SUB231360	Atopic	CSLRA	1.0	expected	82145	b	128								40.31			156.96	248.36	16886																														.m																																											128								29.5			57.97	363.78	9927																														.m																																											117
SUB231361	Atopic	CSLRA	1.0	expected	82937	b	148				2.08		2.94		21.5			324	586	1610					4.36		2.26					6.51							6.94											.m																																											148				3.54				20.6			328	564	1340																														.m																																											237
SUB231362	Atopic	CSLRA	1.0	expected	98014	b	159					1.55			91.4			271	515	371					1.87	3.19			1.06			4.56	3.37						12.5	2.66						13.6	1.82			.m																																											159					2.62			91.2			248	627	472					1.26	5.1						4.23	2.64						17.2	3.69			1.49			16.1	2.85			.m																																											297
SUB231363	Atopic	CSLRA	1.0	expected	102856	b	148				4.36				41			201	1560	13																														.m																																											.m																																											.m																																											236
SUB231364	Atopic	CSLRA	1.0	expected	119548	b	159					1.55			31.6			40.7	344	338					8.24	1.01						11.5	2.12						28.3							27	2.29			.m																																											159								32.9			37	323	261					7.78	1.43						12.7	1.39						29.8	2.41			1.23			25.6	3.75	1.36		.m																																											289
SUB231365	Atopic	CSLRA	1.0	expected	113545	b	159					1.65			229			613	842	228						3.9						1.07	3.52			1.32			3.06	8.64	1.17					8.54	2.25	3.13		.m																																											159					1.69			237			638	929	282						4.36							1.94						6.73	19.3						9.44	2.12			.m																																											281
SUB231366	Atopic	CSLRA	1.0	expected	102710	b	160											103	208	1940																				8.91	37							29.7		.m																																											160											98.6	259	1550							9.35														25.1							23		.m																																											279
SUB231367	Atopic	CSLRA	1.0	expected	100881	b	160								223			480	1540	3770						17.3	416							7.56						247	111						19	529		.m																																											160								229			427	1800	2450						27.6	16.5							11.7						9.22							1.62	31.8		.m																																											280
SUB231368	Atopic	CSLRA	1.0	expected	105932	b	159	1.13				1.43			74.4			295	452	294		1.01			1.37	6.74			1.01			5.35	7.65						8.69	20.8	5.66		1.03			3.8	3.1			.m																																											159					1.19			64.4			250	580	463						11.8	4.75						3.39			1.13			3.42	133	28.2		1.09			1.57	6.19	5.21		.m																																											279
SUB231369	Atopic	CSLRA	1.0	expected	97340	b	160						23.6		63.8			41.4	872	5560							32.6							19.3						69.1	128						13.3	57.5		.m																																											160						25.1		50.6			27.4	1040	8120																														.m																																											274
SUB231370	Atopic	CSLRA	1.0	expected	123558	b	160						25.1		69.8			76.4	830	271							19.3							27.7							25.6							41.6		.m																																											160						42.8		77.1			88.7	697	573							26.4							44.6							16.9							32.4		.m																																											268
SUB231371	Atopic	CSLRA	1.0	expected	124040	b	160						31.2		154			219	1440	165							18.3							31.6							28.7							39.3		.m																																											160						33.1		146			223	1680	140							31.2							32.9							41.2							52		.m																																											267
SUB231372	Atopic	CSLRA	1.0	expected	112985	b	160						24.6		89.3			191	352	7230							40							40.3					9.54	7.52	31.2					8.06	27.5	33.6		.m																																											160						26.7		68.5			154	379	5710							32.6							37.4					11.1	6.35	39.3							7.98		.m																																											263
SUB231373	Atopic	CSLRA	1.0	expected	127250	b	160						26.4		117			232	429	2290							29.7							25.1						7.76	18.3							20.4		.m																																											160						30.9		104			195	381	2460							32.6							30.2						3.24	35.3							32.6		.m																																											263
SUB231374	Atopic	CSLRA	1.0	expected	107427	b	160						23.3		25.8			88	321	133							31.4							18							29.7							36		.m																																											160						37.4		16.7			75.6	260	109							22							37.2							43.7							32.1		.m																																											258
SUB231375	Atopic	CSLRA	1.0	expected	109608	b	171								21.9			54	110	8030						2.44							6.74							10.4							17.7			.m																																											171								36.7			47.7	62.3	2460						1.07	2.86						2.77	10.5						16.5	4.81						18.8	5.82		.m																																											304
SUB231376	Atopic	CSLRA	1.0	expected	127514	b	171					2	13.3		4.13			63.5	250	565		1.05				1.68	20.4						1.89	21.2					6.97	2.12	19.4					8.1	1.9	14		.m																																											171					1.15	9.89		4.35			67.4	222	447						1.62	10.7						1.54	12.9		1.04			8.08	2.67	20.7						2.6	11.5		.m																																											295
SUB231377	Atopic	CSLRA	1.0	expected	122216	b	171					2.37	16.6		37.5			81.2	170	1950						2.46	24.4						2.85	11.3						2.12	28.3						1.86	19.9		.m																																											171					1.33	17		16.2			84.7	139	1870						2.13	31.2						4.62	20.9						2.4	25.9		1.01				2.26	24.2		.m																																											290
SUB231378	Atopic	CSLRA	1.0	expected	135083	b	171	1.01				3.05	23.4		26.9			47.2	119	94.6						7.08	18.2						2.26	17.4						3.25	28.6						4.5	24.7		.m																																											171					1.9	17.6		28.4			42.4	247	116						5.24	21.9						3.21	16.1						2.06	10.9						3.55	25.3		.m																																											289
SUB231379	Atopic	CSLRA	1.0	expected	141912	b	171					2.11	28.6		165			138	1270	4360		1.08				2.17	20.5						2.71	22.4					2.18	3.46	14.8							13.8		.m																																											171	1.05					34		172			287	723	2180		1.1				3.34	26.7		1.2				2	16.1					6.33	2.33	27.2		1.29				4.71	32.6		.m																																											282
SUB231380	Atopic	CSLRA	1.0	expected	83905	b	171								202			480	874	384						9.01							11.4	3.89					4.94	7.49							10.2			.m																																											171								118			232	1950	344						17.2							22.1						4.06	10.8							18			.m																																											281
SUB231381	Atopic	CSLRA	1.0	expected	148402	b	171					1.35	23.2		10.6			79.4	217	4410						2.51	29.3					3.27	1.97	13.8					11.2	3.59	28.9		1.05			1.77	1.9	39.5		.m																																											171					1.62	10.2		14.4			87.4	331	5900		1					27.9		1.05				2.3	16					15.8	2.87	31.2							23.7		.m																																											280
SUB231382	Atopic	CSLRA	1.0	expected	132863	b	171					2.24	15.8		63.4			397	88.3	186					4.14	1.14	19.5					14.7	2.15	20.4		1.11			20.6	2.32	28.1		1			8.45	2.78	28.9		.m																																											171	1.01				1.4	29.5		28.4			135	139	106					7.53	2.98	23.2		1.12			10	1.89	21.7					15.9	1.82	21.2					8	2.13	14.8		.m																																											276
SUB231383	Atopic	CSLRA	1.0	expected	107538	b	184	1.18			1.03				27.8			208	307	691		1.21			1.54				1.26			1.6				1.14			1.99	20.6	10.2		1.46			1.01				.m																																											184				1.43				23			164	235	941					1.75	1.94			1.24			1.41				1.3			1.75	14.6			1.18			1.46	1.01			.m																																											341
SUB231384	Atopic	CSLRA	1.0	expected	118576	b	184				1.94				38.5			109	279	34.2		1.65			1.99				1.29			1.83				1.56			6.6				1.23			4.99				.m																																											184				1.94				44.7			135	264	42.5					1.48	1.11			1.02			1.47				1.37			5.04	1.46			1			4.58				.m																																											342
SUB231385	Atopic	CSLRA	1.0	expected	146613	b	184	1.38			1.13				116			74	897	797		1.72			2.37		13.5					2.53				1.89			4.18	1.11			1.46			2.06		1.64		.m																																											184				1.5				116			83.3	1700	552		1.93			2.05				1.49			2.08		15.1					5.07				1.19			2.62				.m																																											339
SUB231386	Atopic	CSLRA	1.0	expected	138864	b	184				4.53				12.7			61	76.7	337		1.05			1.17	2.5			1.3			1.91				1.55			2.45	3.71	4.43		1.5			1.58				.m																																											184	1.55			4.53				15.3			95.2	90.1	226		1.64			1.57				1.69			2.06				1.06			2.54	1.21			1.25			3.11		8.57		.m																																											337
SUB231387	Atopic	CSLRA	1.0	expected	139311	b	184	1.57			3.19				66.8			38.5	1690	43.4		1.21			3.22		4.85		1.74			3.5		8.57		1.58			7.62	1.77			1.48			2.97		14.7		.m																																											184	1.14			3.17				72.8			41.2	1410	30		1.2			3.4		1.64		1.41			3.24		10.2		1.99			6.23	1.87			1.21			2.89		14.7		.m																																											335
SUB231388	Atopic	CSLRA	1.0	expected	82673	b	184	1.33			2.4		23		13.5			27.3	111	18800		1.04			1.78	6.66	7.74		1.63			2.24				1.34			3.82	6.5	31.4		1.8			2.65	1.48	45.6		.m																																											184	1.28			2.45		6.92		27.9			92.6	170	31900		1.15			1.33	4.5	25.9		1.06			1.47	1.61			2.37			6.44	6.98	39.8		1.18			2.6	1.59	43.9		.m																																											332
SUB231389	Atopic	CSLRA	1.0	expected	125283	b	184	1			1.76		33.1		18.7			104	193	17600		1			1.68	1.63	16.5					2.25	1.13	14.5		1.03			8.71	11.9	40.6		1.62			3.23	3.28	27.3		.m																																											184	1.33			1.37		33.1		17.4			110	203	9100					1.98	1.79	24		1.8			1.41	1.11	20.7		2.25			11.5	16	32.7		1.17			4.43	1.17	33.1		.m																																											330
SUB231390	Atopic	CSLRA	1.0	expected	109836	b	184	1			2.73	1.48	33.5		45			97	193	452		1.39			1.46	3.03	38.9		1.09			2.89		31.4		1.51			7.81	44.3	31.8		1.19			2.6	1.25	28.5		.m																																											184	1.29			2.86	1.03	43.5		43.8			144	240	888		1.78			2.49	1.77	14.9		1.29			2.6		23.1		1.86			5.89	19.1	28.1		1.05			2.54	1.54	21.5		.m																																											329
SUB231391	Atopic	CSLRA	1.0	expected	123701	b	184	1.71			2.08		19		4.27			42.3	79.6	2320		1.33			2.41	1.59	41		1.48			1.74	1.38	54.9		1.36			8.74		46.5		1.16			2.25	2.44	35.6		.m																																											184	1.89			2.38	1.24	39.8		6.42			58.5	106	2280		1.12			1.82	1.58	43.1		1.36			1.48		25.6		1			5.91	1.7	44.8		1.55			2.94	1.11	25.6		.m																																											328
SUB231392	Atopic	CSLRA	1.0	expected	127361	b	186						101		143			530	508	5520						8.05								34.5					16.9	50.6	45.8					6.52	47.6	378		.m																																											186						23.4		132			475	836	8330							95.2							63.4		7.83			81.9	99.8	41.8							9.94		.m																																											331
SUB231393	Atopic	CSLRA	1.0	expected	82849	b	184				1.82		23.5		84.9			398	666	2550		1.76			2.2	7.87	45.6					2.34	1.29	31.8		1.03			5.24	3.85	33.9					1.98	5.25	36		.m																																											184	1.33			1.4	1.38	40.6		73			297	628	1880		1.57			1.44	1.32	48.1		2.02			3.26	1.9	65.9		1.45			5.14	6.12	38.9		1.31			2.57	11.4	40.6		.m																																											328
SUB231394	Atopic	CSLRA	1.0	expected	157486	b	186						60		83.2			93.3	304	32500														45.4					27.1		6.22					16.6	7.77	20.8		.m																																											186						29		86.8			114	246	41700							45					9.49		56.5					21.5	9.34	51.5					18	6.05	8.31		.m																																											327
SUB231395	Atopic	CSLRA	1.0	expected	213731	b	186						43.4		202			164	971	276					33.6		84.8					27.5		49					31.6		26.2					21.1		127		.m																																											186								266			235	2810	151					14.6		14.8					33.9		30.4					116	48.7	21.4					15.2		27.2		.m																																											323
SUB231396	Atopic	CSLRA	1.0	expected	162956	b	186				19.7		48.6		123			368	334	7560							89.5							97.2						7.96	108							81		.m																																											186				7.93		30.4		170			346	351	5340							81.5							21.8							29.7							89.5		.m																																											324
SUB231397	Atopic	CSLRA	1.0	expected	153975	b	190				1.18				979			707	919	158					1.19														7.46											.m																																											190								1230			789	1060	185																			11.8		4.43					3.31				.m																																											354
SUB231398	Atopic	CSLRA	1.0	expected	226323	b	190								138			504	500	391					10							9.5	15.6						2.02											.m																																											190								141			528	527	232					8.5							11.2	13	10.4					1.39											.m																																											354
SUB231399	Atopic	CSLRA	1.0	expected	210854	b	190								17.6			31.8	237	601					2.99							3.23							29.2							19				.m																																											190								20.6			28.4	296	473					3.39							3.31							28.9							6.37				.m																																											349
SUB231400	Atopic	CSLRA	1.0	expected	210729	b	190								399			591	632	4130																			1.62	6.82										.m																																											190								385			494	562	5580						2.82													1.1											.m																																											343
SUB231401	Atopic	CSLRA	1.0	expected	227536	b	195								109			206	570	146													1.25							1.12							1.72			.m																																											195					1.07			112			168	544	146													1.21							1										.m																																											353
SUB231402	Atopic	CSLRA	1.0	expected	169124	b	195								86.1			227	518	14.6						1.02														1										.m																																											195								127			241	622	12.7						1.06						13.7								1.11							1.14			.m																																											350
SUB231403	Atopic	CSLRA	1.0	expected	172593	b	195					1.16			54.5			57.3	350	22100						1.28							1.14						4.87	4.8						1.68	2	9.4		.m																																											195					1.41	246		57.5			65.3	324	25500						1.18													8.31	1.44						6.16	1.24			.m																																											347
SUB231404	Atopic	CSLRA	1.0	expected	135546	b	195					1.12			1080			768	1420	246					4.22							2.17	1.24						27.1	3.88						6.26	1.48			.m																																											195					1.28			809			655	1210	138					1.47	1.48						4.61							23.8	3.67						9.21	1.5			.m																																											348
SUB231405	Atopic	CSLRA	1.0	expected	248389	b	195					1.06			65.6			145	686	1500						8.93							2.9							1.88							6.92			.m																																											195					1.09			81.7			170	696	1720						5.07							2.49							2.42							7.01			.m																																											336
SUB231406	Atopic	CSLRA	1.0	expected	240517	b	195					1.08	7.48		74.8			122	445	13400						1.39							1.5	3.29					12.2	7.26	6.99					6.17	1.42	2.05		.m																																											195					1.21	6.91		84.5			119	463	15700						1.21	6.59						1.38						17.6	4.72	5.22						1.33	2.8		.m																																											330
SUB231407	Atopic	CSLRA	1.0	expected	220806	b	195								21.7			21.3	120	2330						8.72	1.67						5.73						2.03	2.83	5.38						2.01	6.11		.m																																											195					1.28			29.3			26.6	196	3040						9.23							4.59						1.8	4.85	8.36						1.91	8.04		.m																																											330
SUB231408	Atopic	CSLRA	1.0	expected	239046	b	195					1.24	2.18		14.1			122	343	321						1.54	2.05						1.45	3.61						2.03	2.88					5.89	1.32	2.14		.m																																											195					1.17	4.14		15.9			92	319	246						1.21	5.34						1.1						2.17	1.28	4.1					4.57	2.2	3.37		.m																																											321
SUB231409	Atopic	CSLRA	1.0	expected	240390	b	207						1.36		54			71.1	307	2640																			7.89	6.53										.m																																											207								48.7			68.4	324	2420																			20	4.03						1.42	4.38			.m																																											384
SUB231410	Atopic	CSLRA	1.0	expected	227425	b	207								175			851	526	576																														.m																																											207								158			796	527	1010																														.m																																											368
SUB231411	Atopic	CSLRA	1.0	expected	280795	b	207								30.1			70.7	181	1230																			8.35	18.9	2.98					10.6	4.29	2.46		.m																																											207								40.2			88.8	175	1340																			12.2	26.2	1.38					5.41		1.55		.m																																											364
SUB231412	Atopic	CSLRA	1.0	expected	268705	b	207								25			66.1	105	3540																														.m																																											207								30.9			76.5	99.5	3510																														.m																																											367
SUB231413	Atopic	CSLRA	1.0	expected	270891	b	207						4.84		69			532	277	502							2.81												9.86	4.25	2.63					8.84	1.16	2.33		.m																																											207						3.03		54			425	308	386						1.01	2.46												8.11	17.9	1.72					11.9	1.5	2.33		.m																																											359
SUB231414	Atopic	CSLRA	1.0	expected	154621	b	207						2.07		129			182	470	1230							3.61						1.03							39.1	2.41							3.34		.m																																											207						1.34		122			162	436	1380							1.51							1.85						9.17	4.61							2.67		.m																																											345
SUB231415	Non-atopic	CSLRA	1.0	expected	280227	b	207						1.11		213			711	364	41.6							3.7												14	2.13						4.47				.m																																											207						1.06		234			632	360	180							1.68							3.16					7.61	6.14	3.61					3.29		5.11		.m																																											348
SUB231416	Atopic	CSLRA	1.0	expected	133796	b	207						1.25		95.9			53.2	162	417							1.34							4.06							1.85							4.29		.m																																											207						1.11		90.5			37.2	152	440							2.11							2.54						1.93	3.25						1.18	2.81		.m																																											340
SUB231417	Atopic	CSLRA	1.0	expected	255245	b	204						2.1																					2.51																.m																																											204						4.04																					14																.m																																											315
SUB231418	Atopic	CSLRA	1.0	expected	304818	b	204																																											.m																																											204																																											.m																																											316
SUB231419	Atopic	CSLRA	1.0	expected	301357	b	209					1			48			226	190	179					2.29	1.12						2.13	1.08						4.8	2.01						6.41	1.86			.m																																											209				1	1.17			45.7			216	183	194					1.96	1.2						2.18	1.31						5.04	1.16						6.08	1.32			.m																																											346
SUB231420	Atopic	CSLRA	1.0	expected	240628	b	208								16.8			40.8	112	4810																			1.18	7.19						1.18		2.69		.m																																											208								22.3			36.9	88.1	5000																			2.06	3.73										.m																																											347
SUB231421	Atopic	CSLRA	1.0	expected	257991	b	209					1.27			218			207	816	636					1.08	1.34							1.61						1.1	9.41						1.38	2.57			.m																																											209					1.11			178			143	675	1780						2.48							1.55						1.45	21.6						1.28	4.05			.m																																											345
SUB231422	Atopic	CSLRA	1.0	expected	288840	b	220								1.28			68.6	15.6	4340							1.12														1.8									.m																																											220								2.87			34.9	31.4	2820							1.36																							.m																																											376
SUB231423	Atopic	CSLRA	1.0	expected	299343	b	220								30.6			172	289	67.8					1.36		1.43												7.24							9.75				.m																																											220								32.2			202	319	157																			6.22		1.07					11.8				.m																																											375
SUB231424	Atopic	CSLRA	1.0	expected	129341	b	219								289			243	880	75.9					2.49							3.03							8.01	4.04						7.38	1.81			.m																																											219								281			269	859	84.5					2.45							4.97							6.91	8.2						6.41				.m																																											363
SUB231425	Non-atopic	CSLRA	1.0	expected	334845	b	219								94.2			184	630	151																			5.07							3.68				.m																																											219								78.7			200	521	189																			5.08							5.67				.m																																											364
SUB231426	Atopic	CSLRA	1.0	expected	300863	b	220								85.3			261	329	315																			6.43		1.12					5.37				.m																																											220								80.2			258	391	966																			8.91		1.22					5.26				.m																																											358
SUB231427	Atopic	CSLRA	1.0	expected	301087	b	220						1.91		79			157	294	811												2.23		1.11					14.7	8.27	2.68					11.7		12.2		.m																																											220						1.07		69.4			187	216	1050						1.83	1.69					2.37		1.07																.m																																											352
SUB231428	Atopic	CSLRA	1.0	expected	326582	b	220								44.5			331	130	123							1.2												2.03	13.3	2.4							1.11		.m																																											220						1.07		44.9			392	118	109							1.25												2.92		1.76							2.29		.m																																											351
SUB231429	Non-atopic	CSLRA	1.0	expected	347202	b	221								159			586	280	37																			3.37	3.03						19.7				.m																																											221								128			490	306	20.9																			2.05							4.47				.m																																											354
SUB231430	Non-atopic	CSLRA	1.0	expected	293015	b	224								622			119	2240	353																			4.83							3.86				.m																																											224								625			120	2590	640																														.m																																											355
SUB231431	Non-atopic	CSLRA	1.0	expected	293691	b	221								25.8			79.6	165	12100						2.03							1.41						5.02							7.62				.m																																											221								27.5			95.5	146	11900																			10	1.25						5.23				.m																																											350
SUB231432	Non-atopic	CSLRA	1.0	expected	337216	b	224								25.7			306	196	116														3.23												1.84				.m																																											224								38.8			376	218	207																			1.39							1.66				.m																																											354
SUB231433	Atopic	CSLRA	1.0	expected	326471	b	224								78.7			110	345	493																			5.91							5.38				.m																																											224								64.7			103	368	822																			3.22							5.61				.m																																											350
SUB231434	Non-atopic	CSLRA	1.0	expected	283448	b	224								27.5			232	196	4280					1.85	5.77						2.6							54.5	94.6						14.2				.m																																											224								28.8			255	197	4150					1.8	4.29						2.79	6.7						47.1	107						13.7				.m																																											349
SUB231435	Atopic	CSLRA	1.0	expected	316582	b	224								36.2			279	161	34.3									1.06				1.54	1.74					1.82							1.35				.m																																											224								49.1			270	177	40.1													1.33	1.62					1.39							1.82				.m																																											347
SUB231436	Atopic	CSLRA	1.0	expected	237100	b	220								6.82			136	102	3270																			9.43							7.14				.m																																											220								8.22			120	90.1	2630																			8.65							6.92				.m																																											348
SUB231437	Atopic	CSLRA	1.0	expected	336348	b	225					1.35	1.55		89.4			1470	222	1150						2.93						1.08	1.89						6.34	12.5						3.13	1.99			.m																																											225					1.53	3.07		150			406	313	121					1.27	2						1.32	1.51						12.6	15.3	4.02					3.76	1.99	4.72		.m																																											338
SUB231438	Non-atopic	CSLRA	1.0	expected	371639	b	225					1.68			21.1			175	193	477						1.37							1.63						2.43	2	8.79					1.72	2.01	3.43		.m																																											225					1.3	4.26		19.8			120	185	3060						1.37							1.27						2.36	1.99	6.35					1.63	1.52	3.79		.m																																											335
SUB231439	Non-atopic	CSLRA	1.0	expected	347070	b	225					1.93	3.43		114			412	232	987						2.96							2.01						3.93	1.43	4.61					6.08	8.64	13.3		.m																																											225					1.77			80.4			394	217	1040						2.02	2.22					1.05	2.02						2.68	2.14						3.71	1.24	6		.m																																											328
SUB231440	Atopic	CSLRA	1.0	expected	326749	b	225					1.12			18.9			78	185	505						1.76							1.76						1.07	6	9.37						1.23			.m																																											225								24			82.3	198	691						2.33	1.2						1.75							1.84							1.63			.m																																											327
SUB231441	Atopic	CSLRA	1.0	expected	244195	b	225					1.38			213			633	1180	601						2.84							1.51						12	3.43						5.08	1.89			.m																																											225					1.53			236			815	1240	995					1.31	1.63						1.04	2.09						9.96	2.56						5	1.86			.m																																											337
SUB231442	Atopic	CSLRA	1.0	expected	252954	b	224								16.1			63.1	150	1100																			2.82		3.9					4.3		6.38		.m																																											224								15.8			51.3	150	1110												1.04							2.8	2.75	5.95					5.34		6.38		.m																																											347
SUB231443	Atopic	CSLRA	1.0	expected	316804	b	225					1.03			111			122	560	465					1.65	1.18							1.76						10.4	3.05						5.45	1.26			.m																																											225								110			131	605	469						1.36						2.87							9.18	2.06						4.75	2.06			.m																																											324
SUB231444	Atopic	CSLRA	1.0	expected	258111	b	225					1.71			14.5			82.5	150	3290						1.88							1.85						2.18	6.74						3.73	6.6			.m																																											225					2.39			11.7			91.4	102	3240						1.68													5.87	88.6	6.12					4.08	5.82			.m																																											321
SUB231445	Atopic	CSLRA	1.0	expected	349861	b	225					1.36	6		25.8			60.7	93.2	3680						1.58	4.37						1.39						2.43	1.54						6.69	1.74	9.48		.m																																											225					1.59			30.3			66.9	123	4180						1.87	3.9						1.8	1.96					3.57	2.11						4	1.85	9.83		.m																																											312
SUB231446	Non-atopic	CSLRA	1.0	expected	342896	b	225					2.09			89			109	204	253						1.76							1.18						3.45	2.09						3.29				.m																																											225					1.58	3.07		75			91.1	198	198						1.53	5.19						1.45						4.56	1.97						2.95	1.35			.m																																											313
SUB231447	Non-atopic	CSLRA	1.0	expected	404534	b	225					2.13	9.02		11.1			141	293	3230					1.81	1.92							2.05						4.64	12						2.5	1.89	5.31		.m																																											225					1.9	7.98		14.3			192	294	4560					1.36	3.41	6.93					1.04	2.44	2.22					4.11	17.9	7.4					3.4	2.68	3.67		.m																																											301
SUB231448	Atopic	CSLRA	1.0	expected	330315	b	240	2.75							18.2			43.7	137	397		3.02			14.6	10.2	1.9		2.68			3.14	1.53						2.8	1.78			2.52			11.1	1.73			.m																																											240	3.49				1.29	2.55		20.2			36.4	157	244		3.29			1.97	1.48			2.81			2.1	1.18			2.55			13.7	3.03						8.25	1.68	1.99		.m																																											335
SUB231449	Atopic	CSLRA	1.0	expected	331889	b	240	3.94			2.27	1.05			6.09			99.4	34.4	61.2		2.68			8.21				2.02			13.7							20.3	1.56			2.35			10.7	1.29			.m																																											240	4.25			2.28	2.34			3.95			91.7	29	89.4		3.08			8.87	1.76			3.08			13.5	1.78			4.29			19.8	2.46			3.83			9.32	1.66	2.23		.m																																											321
SUB231450	Atopic	CSLRA	1.0	expected	414722	b	241	2.07			2.74	1.61			28.8			502	224	2820					1.84	1.76			2.29			3.86	1.91			1.85			31.5	759	198					6.22	14.8	4.22		.m																																											241				3.96	1.56			36.3			652	219	2260		2.14			3.61	2.54						4.65	1.47						39.9	715	260					4.51	16.3	1.34		.m																																											312
SUB231451	Non-atopic	CSLRA	1.0	expected	406475	b	240					2.54			17.2			84.1	204	2750		3.05				2.17	1.73		4.39			1.27	1.73	1.34					2.93	259	76.6						6.59			.m																																											240	2.35				2.17			19.7			82.6	234	2530		3.83				2.84			2.81			3.78	2.57	2.55		4.01			1.42	217	31.6						9.12			.m																																											311
SUB231452	Non-atopic	CSLRA	1.0	expected	402869	b	241	1.13				1.37			4.64			111	78.8	6850						1.07							1.12						7.68	1.13						2.77	1.35			.m																																											241								4.71			97.2	81.9	6190					2.13	1.23							1.12						6.24	1.78	1.62					2.61	1.35			.m																																											303
SUB231453	Atopic	CSLRA	1.0	expected	407123	b	241				1.57	1.49			12.7			59.9	263	3170						1.33							1.06						2.18	33.7	5.84						3.96			.m																																											241					1.29			13.1			56.6	289	2580													1.52						2.02	26.9	6.39						2.95			.m																																											289
SUB231454	Atopic	CSLRA	1.0	expected	434151	b	241					1.04			6.99			70.6	428	166						1.07							1.06							1.09							1.07			.m																																											241					1.09			8.77			62.1	377	128						1.01							1							4.42							1.03			.m																																											290
SUB231455	Non-atopic	CSLRA	1.0	expected	400972	b	241					1.24			3.44			27.1	82.1	1050					4.47	1.22						3.83	1.77	75.2		2.11			3.83	3.91	4.99		2.25			6.05	5.25	20.8		.m																																											241					1.01			5.25			28.9	89.2	730					5.15	1.58						7.52	1.05			2.11			5.38	4.29	3.69		2.02			3.33	1.88			.m																																											280
SUB231456	Non-atopic	CSLRA	1.0	expected	443229	b	225				1.04	2.12	9.14					96	32.2	309					1.09	1.81	8.09					1.28	1.44	9.72					1.36	2.74	2.71					1.25	2.1	6.24		.m																																											225					2.19	3.43		4.8			91.5	42.2	321						1.3	15.5					1.02	1.69	4.96					1.66	3.22	9.14						3.76	4.14		.m																																											238
SUB231457	Non-atopic	CSLRA	1.0	expected	420888	b	241				13.3	1.71			13.4			140	357	3850		2.11			10.1	4.01			2.37			12.9	2.55			2.96			44.3	198	19.6		2.26			16.3	18.7			.m																																											241	2.88			10.5	1.91																																						.m																																											273
SUB231458	Atopic	CSLRA	1.0	expected	420152	b	225				5.05	6.18	74.2		22.8			278	284	4600					3.69	29.5	42.6					4.4	18.5	61.2					7.09	334	2230					5.25	42.9	1180		.m																																											225				5.2	5	60.6		23.9			237	260	4520					2.5	20.9	19					3.16	14.3	35.9					6.6	359	2000					2.68	11.5	51.2		.m																																											235
SUB231459	Non-atopic	CSLRA	1.0	expected	409837	b	241				18.9	3.06	7		18.2			335	273	1560					1.14	2.93						1.92	6.39	5.74					4.2	36.8	64.5					10.6	210	358		.m																																											241	2.14			18.7	2.65	4.91		19.1			351	216	2470		1.68			2.22	5.88			2.05				6.07	5.3					12.7	361	533		2.07			2.33	16.4	13.5		.m																																											270
SUB231460	Non-atopic	CSLRA	1.0	expected	409958	b	244					1.77			42.3			124	602	12200					3.68	1.35						2.74							1.77	35.8	5.8					1.85	2.03			.m																																											244	2.05				1.74			76.7			153	346	16500					2.31	1.15			2.54			2.87	1.5						2.05	13.7	2.88		2.26			3.13	1.68			.m																																											267
SUB231461	Atopic	CSLRA	1.0	expected	443118	b	244				4.45	2.26			19.9			113	399	11100					5.16	9.02						7.01	5.47						12	286	194					5.21	21.8			.m																																											244				4.57	2.93			31.6			109	392	14800					5.34	4.32			2.08			5.01	3.31	1.12					13.3	214	251					11.5	54.1	55.4		.m																																											260
SUB231462	Non-atopic	CSLRA	1.0	expected	405169	b	241					1.55			236			691	944	116					1.66	1.57			2.38			2.33	1.38			2.49			5.03	178	136					2.64	11.6			.m																																											241					1.49			213			622	1450	129					1.14	1.94			2.2			2.57	2.06	1.25		2.54			5.46	66.7	5.41		2.2				6.85			.m																																											304
SUB231463	Atopic	CSLRA	1.0	expected	456224	b	244				3.2				73.3			82.7	164	6230					3.25							3.9							7.67	143	89.8					3.72	1.49			.m																																											244				3.32				66			83.4	166	7070					3.73							3.68							5.61	98.5	7.46					4	3.43			.m																																											244
SUB231464	Non-atopic	CSLRA	1.0	expected	441498	b	244								35.5			82.2	202	30100					6.48							6.72							7.78	79.8	9.55					12.8	46.9	79.3		.m																																											244								21.1			87.1	201	41500					4.38	4.54						6.68							4.83	42.7	11.7					8.1	13.4	43.1		.m																																											239
SUB231465	Non-atopic	CSLRA	1.0	expected	438314	b	225				3.31	1.93	10.2		13.5			47.1	204	5210					1.61	1.44	9.14						1.71	8.79						1.76	1.11		2.09				1.56	2.83		.m																																											225				2.84	2.02	6		13.3			48.4	223	4020					1.85	1.99	3.07					1.04	1.79	14.1						1.53			1.6				1.6	2.08		.m																																											192
SUB231466	Atopic	CSLRA	1.0	expected	437795	b	225	1.92				1.32	2.65		61.4			139	793	468						2.78	2.51						1.51	2.08						3.47	2.34						32.3	4.5		.m																																											225					1.76	1.32		120			185	1080	373						1.51	2.96						1.87	2.08		1.69				14							1.87	1.36		.m																																											190
SUB231467	Atopic	CSLRA	1.0	expected	450594	b	244				2.53				33.4			218	226	12200					6.1							8.61							8.82	62.6	24					8.28	7.93	2.44		.m																																											244				2.57				33.7			212	237	13400					6.43							8.21				1.89			9.69	117	37.3					7.19	14.4	21.2		.m																																											227
SUB231468	Atopic	CSLRA	1.0	expected	429803	b	244				6.85		1.4		19.1			283	178	388		3.75			5.61		1.93					6.28				1.56			14.5	5	1.6					13.5		1.98		.m																																											244				11.9				18			251	161	377					5.77							6.52							15.5	11.6	2.44					8.72				.m																																											217
SUB231469	Non-atopic	CSLRA	1.0	expected	444155	b	244				2.21				13.1			128	124	7210					3.05				1.89			1.81		1.17					4.06	1.78	19.7					1.35	1.59	9.97		.m																																											244				2.32		4.2		13.7			129	127	8660					1.6				1.18			1.53				2.93			3.27	2.15	11.6					1.96	2.17	38.7		.m																																											210
SUB231470	Non-atopic	CSLRA	1.0	expected	434373	b	244	1.89			5.73				8.69			191	132	24600					5.28		1.23					10.9							19	98.2	33.8					8.84	1.6	1.98		.m																																											244				4.7				7.76			194	138	18700					6.36							11.3	1.04						17.2	62	17.7		1.93			7.16	3.3	5.15		.m																																											187
